var title_f5_20_5440="Contents: Primary care hematology";
var content_f5_20_5440=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care hematology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care hematology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Blood smear and bone marrow",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38313\">",
"           Evaluation of the peripheral blood smear",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coagulation disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/4/24650\">",
"           Acquired inhibitors of coagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/35/28218\">",
"           Activated protein C resistance and factor V Leiden",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/59/37818\">",
"           Anticoagulants other than heparin and warfarin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18153\">",
"           Anticoagulation during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1258\">",
"           Anticoagulation in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/36/24136\">",
"           Antithrombin (ATIII) deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/3/5178\">",
"           Approach to the adult patient with a bleeding diathesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/19/15674\">",
"           Approach to the adult patient with thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/30/35305\">",
"           Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/20/25929\">",
"           Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1322\">",
"           Clinical manifestations and diagnosis of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/31/23034\">",
"           Clinical manifestations of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24794\">",
"           Clinical presentation and diagnosis of von Willebrand disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/36/4682\">",
"           Clinical use of coagulation tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27096\">",
"           Diagnosis of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/36/6730\">",
"           Drug-induced thrombosis and vascular disease in patients with malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/41/11930\">",
"           Evaluation of the patient with established venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40890\">",
"           Heparin-induced thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/43/35514\">",
"           Hypercoagulable disorders associated with malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23752\">",
"           Management of inherited thrombophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43786\">",
"           Overview of the causes of venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/56/8073\">",
"           Pathogenesis and etiology of disseminated intravascular coagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/43/32439\">",
"           Preoperative assessment of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/52/841\">",
"           Protein C deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/55/13176\">",
"           Protein S deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20903\">",
"           Screening for inherited thrombophilia in asymptomatic populations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/8/33930\">",
"           Therapeutic use of heparin and low molecular weight heparin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/17/42266\">",
"           Therapeutic use of warfarin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38442\">",
"           Treatment of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23754\">",
"           Treatment of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21866\">",
"           Treatment of von Willebrand disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematologic malignancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20042\">",
"           AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38346\">",
"           AIDS-related lymphomas: Treatment of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/9/19609\">",
"           Clinical manifestations and diagnosis of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1018\">",
"           Clinical manifestations and diagnosis of primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23642\">",
"           Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30362\">",
"           Induction therapy for acute myeloid leukemia in younger adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29206\">",
"           Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/39/28280\">",
"           Malignancy after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25450\">",
"           Management of the complications of the myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36922\">",
"           Prognosis and treatment of primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34425\">",
"           Prognosis of the myelodysplastic syndromes in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14935\">",
"           Staging and prognosis of Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29146\">",
"           Treatment of acute myeloid leukemia in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/53/9049\">",
"           Treatment of high or very high risk myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31210\">",
"           Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Leukemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/58/20393\">",
"           Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/6/24680\">",
"           Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21322\">",
"           Overview of the myeloproliferative neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41225\">",
"           Overview of the treatment of chronic myeloid leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lymphoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/61/27610\">",
"           Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/18/15658\">",
"           Initial evaluation and staging of non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34346\">",
"           Approach to the adult patient with splenomegaly and other splenic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34040\">",
"           Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/25/4505\">",
"           Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/50/39719\">",
"           Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/47/762\">",
"           Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr������m macroglobulinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/35/27194\">",
"           Overview of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37626\">",
"           Treatment and prognosis of Waldenstr������m macroglobulinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/52/36682\">",
"           Treatment of the mixed cryoglobulinemia syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Plasma cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/60/4041\">",
"           Clinical course and management of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/13/35034\">",
"           Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15290\">",
"           Diagnosis of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/58/10154\">",
"           Recognition of monoclonal proteins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Platelet disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/19/15674\">",
"           Approach to the adult patient with thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/6/24681\">",
"           Approach to the patient with thrombocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/13/30938\">",
"           Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18890\">",
"           Diagnosis and clinical manifestations of essential thrombocythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/59/19385\">",
"           Evaluation and management of thrombocytopenia by primary care physicians",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40890\">",
"           Heparin-induced thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/28/32202\">",
"           Prognosis and treatment of essential thrombocythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/25/39322\">",
"           Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Red cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4710\">",
"           Alcohol abuse and hematologic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/13/9434\">",
"           Anemia of chronic disease (anemia of chronic inflammation)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/20/38213\">",
"           Anemias due to decreased red cell production",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/46/29418\">",
"           Approach to the adult patient with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/3/18489\">",
"           Approach to the diagnosis of hemolytic anemia in the adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26234\">",
"           Causes and diagnosis of anemia due to iron deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/13/38106\">",
"           Clinical manifestations and diagnosis of the thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/60/28617\">",
"           Clinical manifestations of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/0/5130\">",
"           Diagnosis and treatment of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42856\">",
"           Diagnosis of sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24777\">",
"           Diagnostic approach to the patient with polycythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/32/9738\">",
"           Diagnostic approach to the patient with suspected polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/32/11786\">",
"           Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38313\">",
"           Evaluation of the peripheral blood smear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/16/21767\">",
"           Macrocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/45/35543\">",
"           Mean corpuscular volume",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42170\">",
"           Overview of the clinical manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39946\">",
"           Overview of the management of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/14/23782\">",
"           Physiology of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28554\">",
"           Prognosis and treatment of polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/37/21082\">",
"           Regulation of iron balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12535\">",
"           Screening for hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/5/9305\">",
"           Spiculated cells (echinocytes and acanthocytes) and target cells",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25578\">",
"           Treatment of anemia due to iron deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/39/7802\">",
"           Treatment of beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/32/18952\">",
"           Treatment of hereditary hemochromatosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         White cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/12/3274\">",
"           Approach to the patient with lymphocytosis or lymphocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29511\">",
"           Approach to the patient with neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35705\">",
"           Causes of neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42966\">",
"           Cyclic neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31303\">",
"           Definition and mechanisms of leukocytosis and neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21850\">",
"           Drug-induced neutropenia and agranulocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39080\">",
"           Evaluation of peripheral lymphadenopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38313\">",
"           Evaluation of the peripheral blood smear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42520\">",
"           Immune neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18170\">",
"           Overview of neutropenia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-4D150CBEEA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_20_5440=[""].join("\n");
var outline_f5_20_5440=null;
var title_f5_20_5441="Tilting stretch exercise";
var content_f5_20_5441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tilting stretch exercise for congenital muscular torticollis with a tight right sternocleidomastoid muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 639px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tilt the head away from the side of the shortened muscle (the infant's right) until the child's ear on the unaffected side (left) touches the shoulder of the unaffected side (left).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5441=[""].join("\n");
var outline_f5_20_5441=null;
var title_f5_20_5442="Closure rectovaginal fistula2";
var content_f5_20_5442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of a small rectovaginal fistula through a transvaginal approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Second layer of the closure, which inverts the first layer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5442=[""].join("\n");
var outline_f5_20_5442=null;
var title_f5_20_5443="Inflammatory bowel disease and pregnancy";
var content_f5_20_5443=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/20/5443/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5443/contributors\" id=\"au6616\">",
"       Mark A Peppercorn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/20/5443/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5443/contributors\" id=\"se6705\">",
"       Paul Rutgeerts, MD, PhD, FRCP",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5443/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/20/5443/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5443/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?5/20/5443?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Inflammatory bowel disease (IBD) is the name for conditions that cause inflammation of the digestive tract, including Crohn's disease and ulcerative colitis (UC). Many women worry about how the changes of pregnancy will affect their inflammatory bowel disease and if IBD treatments will harm their baby. With appropriate therapy, most women can have a normal pregnancy and deliver a healthy baby.",
"    </p>",
"    <p>",
"     IBD therapy during pregnancy is most successful when a woman receives regular medical care and follows her treatment plan closely. Before becoming pregnant, women with IBD should discuss plans for their care with a healthcare provider. Women who discover that they are pregnant should continue their IBD medications until speaking to a healthcare provider.",
"    </p>",
"    <p>",
"     This topic review discusses the relationship between inflammatory bowel disease and pregnancy. Topics that discuss the signs, symptoms, and treatment of these conditions are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      \"Patient information: Crohn's disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      FERTILITY AND INFLAMMATORY BOWEL DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     In most cases, inflammatory bowel disease (IBD) does not affect a woman's ability to become pregnant. However, a man's fertility can be affected by one of the drugs used to treat UC, sulfasalazine (Azulfidine). This medication causes sperm abnormalities in about 80 percent of men. These abnormalities resolve when the drug is discontinued.",
"    </p>",
"    <p>",
"     Extensive abdominal or pelvic surgery (eg, removal of the colon) can increase the risk of impotence (inability to maintain an erection) in men. In women, extensive surgery can increase the risk of infertility, usually as a result of the development scar tissue.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Genetics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men and women with IBD have a risk of passing a susceptibility to IBD to their baby through their genes. First-degree relatives (children, siblings) of people with IBD are between 3 and 20 times more likely to develop the disease compared to relatives of people with no history of IBD.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      PREGNANCY AND INFLAMMATORY BOWEL DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     The severity and extent of a woman's disease when she becomes pregnant appears to influence the course of her disease during pregnancy. About two-thirds of women in remission will stay in remission, and women with active disease are likely to have continued active disease during pregnancy. Thus, doctors usually recommend that women try to conceive while their disease is in remission.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Care before pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;These recommendations apply to any woman who is considering pregnancy.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       All women should take a supplement containing at least 400 mcg of folic acid (the amount in a prenatal vitamin). Taking folic acid can reduce the risk of a specific birth defect, called a neural tube defect. Folic acid should be started before trying to conceive and continued until at least the end of the first trimester. Most prenatal vitamins contain adequate folic acid.",
"      </li>",
"      <li>",
"       Women should stop smoking and consuming alcohol or any recreational drugs (eg, marijuana) before trying to become pregnant.",
"      </li>",
"      <li>",
"       Women who take prescription or non-prescription medications should review these with a healthcare provider. Some medications are safe during pregnancy while others are not. In some cases, an alternate medication can be substituted for an unsafe drug.",
"      </li>",
"      <li>",
"       Caffeine intake should be limited to less than 250 mg per day while trying to become pregnant and during pregnancy. Table 1 lists the caffeine content of several common beverages (",
"       <a class=\"graphic graphic_table graphicRef58574 \" href=\"UTD.htm?15/56/16268\">",
"        table 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Blood testing for rubella (German measles), varicella (chicken pox), HIV, hepatitis B, and inherited genes (eg, cystic fibrosis) may be recommended before pregnancy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Effect of IBD on pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Studies disagree about the effects of inflammatory bowel disease (IBD) on the growth and development of a fetus and the outcome of a pregnancy. In general, the health of the baby and risk of premature delivery depends upon the type, severity, and extent of IBD before and during pregnancy and the treatments used during pregnancy. Women with more severe disease have an increased risk of delivering prematurely and having a low birth weight infant.",
"    </p>",
"    <p>",
"     In some cases, studies of IBD and pregnancy include only women with UC, only women with Crohn's disease, or women with both. In this topic review, we will note when the information applies to a particular disease. In these cases, it is not clear how or if women with other types of IBD are affected.",
"    </p>",
"    <p>",
"     Women with Crohn's disease are at increased risk for having a low birth weight infant and delivering prematurely. In studies, significantly more infants of mothers with Crohn's disease weighed less than 2500 grams (5.5 pounds) and were born prematurely [",
"     <a class=\"abstract\" href=\"UTD.htm?5/20/5443/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Women whose IBD is in remission at the time of conception are likely to remain in remission during pregnancy. Approximately 33 percent of women with ulcerative colitis relapse during pregnancy, commonly during the first trimester [",
"     <a class=\"abstract\" href=\"UTD.htm?5/20/5443/abstract/2\">",
"      2",
"     </a>",
"     ]. The course of a woman's first pregnancy does not necessarily predict the course of future pregnancies.",
"    </p>",
"    <p>",
"     In contrast, women whose IBD is active at the time of conception are likely to have active disease during pregnancy. Surgical treatment, including removal of the colon, is possible during pregnancy, although there is an increased risk of premature labor or miscarriage if surgery is performed. Most women who have had surgery for ulcerative colitis before pregnancy can have a normal pregnancy and delivery, including a vaginal delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Care during pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;During pregnancy, care of women with IBD may be shared between a gastroenterologist and an obstetrical provider. Visits with the gastroenterologist are scheduled based upon the severity of disease during pregnancy. Most women are seen by their obstetrical provider every two to four weeks until 28 weeks of pregnancy. Between 28 and 36 weeks, most women are seen every two weeks. Women are usually seen once per week between 36 weeks and delivery. At every visit, blood pressure and urine testing will be done.",
"    </p>",
"    <p>",
"     To monitor the baby's growth during pregnancy, it is important to have an accurate due date. Women who cannot remember the date of their last menstrual period or are unsure of when the baby was conceived should have an ultrasound before 12 weeks of pregnancy; the due date is most accurate when measured during this time.",
"    </p>",
"    <p>",
"     After 10 to 12 weeks of pregnancy, the baby's heart rate will be measured at every visit. An ultrasound is usually recommended between 18 and 20 weeks of pregnancy to ensure that the baby is growing and developing normally.",
"    </p>",
"    <p>",
"     Some women, especially those who take steroids or have moderate to severe disease flares during pregnancy, will have ultrasound monitoring of the baby's growth every four weeks after 18 to 20 weeks of pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Testing during pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Flexible sigmoidoscopy appears to be safe during pregnancy, although colonoscopy and x-rays should be avoided, if possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Monitoring baby's well-being",
"     </span>",
"     &nbsp;&mdash;&nbsp;A baby's well-being is monitored during regular medical visits throughout pregnancy. Women who are greater than 24 weeks pregnant should monitor the baby's movements every day. If the baby is not moving normally, contact your obstetrical provider immediately.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with IBD often require medications to control their disease. Some of these medications are probably safe during pregnancy and breastfeeding. In other cases, there is not enough information about the medication to determine if they are safe or not. Women who take one or more of these medications during pregnancy should discuss their concerns with a healthcare provider.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Sulfasalazine &ndash; Women who wish to become pregnant can continue taking sulfasalazine during pregnancy and while breastfeeding. Sulfasalazine does not increase the risk of any complications of pregnancy or birth defects.",
"      </li>",
"      <li>",
"       Antibiotics &ndash; Antibiotics are frequently required in the treatment of Crohn's disease and are sometimes used for people with UC. The most common antibiotics used for treatment of IBD are ciprofloxacin and metronidazole. Short courses of metronidazole are probably safe for use during pregnancy. However, ciprofloxacin is not recommended for pregnant or breastfeeding women.",
"      </li>",
"      <li>",
"       5-ASA &ndash; The safety of the 5-ASA drugs during pregnancy and breastfeeding is still being studied. Preliminary studies suggest that they are safe when taken during pregnancy and that women should continue taking these drugs during pregnancy. However, women who take 5-ASA medications should speak to their clinician before trying to conceive.",
"       <br/>",
"       <br/>",
"       If 5-ASA medications are taken during breastfeeding, the American Academy of Pediatrics recommends monitoring the infant's stool consistency. There have been reports of diarrhea in breastfeeding infants of women who took rectal 5-ASA.",
"      </li>",
"      <li>",
"       Steroids &ndash; Some studies have suggested that there may be a very small increased risk of cleft lip or cleft palate in the babies of mothers who took oral steroid medications during the first 13 weeks of pregnancy [",
"       <a class=\"abstract\" href=\"UTD.htm?5/20/5443/abstract/3\">",
"        3",
"       </a>",
"       ]. Two studies found a slightly increased risk of premature delivery, and one study found a slightly increased risk of having a low birth weight baby [",
"       <a class=\"abstract\" href=\"UTD.htm?5/20/5443/abstract/4\">",
"        4",
"       </a>",
"       ]. However, the researchers could not rule out the possibility that these effects were related to the woman's underlying medical condition rather than use of the drug.",
"       <br/>",
"       <br/>",
"       Women who take steroids during pregnancy may be more likely to develop gestational diabetes and high blood pressure, although these conditions can be detected and managed with regular medical visits [",
"       <a class=\"abstract\" href=\"UTD.htm?5/20/5443/abstract/2\">",
"        2",
"       </a>",
"       ]. Women who are taking steroids during pregnancy will need to be given a \"stress dose\" of steroids by IV (into a vein) during labor and delivery. The increased dose helps the body respond normally to the physical stresses of childbirth.",
"       <br/>",
"       <br/>",
"       Steroids (eg, prednisone) are probably safe to take during breastfeeding.",
"      </li>",
"      <li>",
"       Azathioprine and 6-mercaptopurine &ndash; Azathioprine and 6-mercaptopurine can be continued during pregnancy if other types of treatment cannot be used. However, some studies have suggested that these drugs can cause birth defects and miscarriage. Men and women are often advised to stop taking these medications at least three months before trying to conceive, if they have experienced long-lasting remission. Women taking azathioprine and 6-mercaptopurine are often advised to avoid breastfeeding, although there are no good data about the risks of these medications in a nursing infant.",
"      </li>",
"      <li>",
"       Infliximab &ndash; Infliximab is probably safe during pregnancy although there are limited data. In general, infliximab is given during pregnancy only if it is clearly needed. It is not clear if infliximab is excreted into breast milk. The potential effects of infliximab in an infant are also unknown.",
"      </li>",
"      <li>",
"       Adalimumab &ndash; Studies in monkeys have not revealed harm to the fetus when adalimumab was given during pregnancy. There are no well-controlled studies in humans. In general, adalimumab is given during pregnancy only if it is clearly needed.",
"       <br/>",
"       <br/>",
"       It is not clear if adalimumab is excreted into breast milk. The potential effects of infliximab in an infant are also unknown.",
"      </li>",
"      <li>",
"       Certolizumab pegol &ndash; There are no well-controlled studies of certolizumab pegol in pregnant or breastfeeding women. In general, certolizumab is given during pregnancy only if it is clearly needed. It is not known whether certolizumab pegol is excreted into breast milk.",
"      </li>",
"      <li>",
"       Antidiarrheal drugs &ndash; Antidiarrheal drugs such as diphenoxylate with atropine (Lomotil&reg;) and loperamide (Imodium&reg;) have questionable safety during pregnancy and breastfeeding. Alternate drugs, such as Kaopectate and psyllium (Metamucil), are usually recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      LABOR, DELIVERY, AND THE POSTPARTUM PERIOD",
"     </span>",
"    </p>",
"    <p>",
"     Pregnant women with inflammatory bowel disease (IBD) should discuss their labor and delivery plans with their healthcare provider. IBD may affect a provider's choice of medications and treatments during labor, delivery, and the postpartum period.",
"    </p>",
"    <p>",
"     In women with Crohn's disease, the type of delivery (vaginal versus Cesarean) depends upon the health of the tissues around the vagina and anus, the patient and physician's preference, and the woman and baby's progress during labor. If Crohn's disease affects the areas around the vagina or if a woman has an ileoanal pouch, a Cesarean delivery may be preferred to reduce the risk of developing fistulas.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;There does not appear to be any risk that IBD will worsen as a result of breastfeeding. Breastfeeding is strongly encouraged because there are a number of benefits for both women and infants.",
"    </p>",
"    <p>",
"     Limited data from a small series of patients suggest that infliximab was not transferred from mother to child through breast milk [",
"     <a class=\"abstract\" href=\"UTD.htm?5/20/5443/abstract/5\">",
"      5",
"     </a>",
"     ]. However, women who take medications for IBD should discuss the safety of these medications for their breastfeeding infant with an experienced healthcare provider. In addition, because the quality of information regarding medication safety in breastfeeding varies, women are encouraged to consult a reliable source of up-to-date information. LactMed is provided by the National Library of Medicine and is available on the internet (",
"     <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\">",
"      file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Comprehensive information about breastfeeding is available in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H131\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2875712\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2875704\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=see_link\">",
"      Fertility, pregnancy, and nursing in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Colon and Rectal Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.fascrs.org/\">",
"      www.fascrs.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/\">",
"      www.gastro.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Crohn's and Colitis Foundation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ccfa.org/\">",
"      www.ccfa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?5/20/5443/abstract/1-4,6\">",
"      1-4,6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?5/20/5443?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5443/abstract/1\">",
"      Fonager K, S&oslash;rensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998; 93:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5443/abstract/2\">",
"      Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5443/abstract/3\">",
"      Bakhireva LN, Jones KL, Schatz M, et al. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol 2005; 116:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5443/abstract/4\">",
"      Perlow JH, Montgomery D, Morgan MA, et al. Severity of asthma and perinatal outcome. Am J Obstet Gynecol 1992; 167:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5443/abstract/5\">",
"      Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009; 43:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5443/abstract/6\">",
"      Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f5_20_5443=[""].join("\n");
var outline_f5_20_5443=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           FERTILITY AND INFLAMMATORY BOWEL DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           PREGNANCY AND INFLAMMATORY BOWEL DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           LABOR, DELIVERY, AND THE POSTPARTUM PERIOD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?15/56/16268\" title=\"table 1\">",
"           Caffeine source amount PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f5_20_5444="Urothelial CIS B";
var content_f5_20_5444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5444=[""].join("\n");
var outline_f5_20_5444=null;
var title_f5_20_5445="Azelastine (nasal): Pediatric drug information";
var content_f5_20_5445=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azelastine (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8022?source=see_link\">",
"    see \"Azelastine (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/54/12132?source=see_link\">",
"    see \"Azelastine (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7976934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Astelin&reg;;",
"     </li>",
"     <li>",
"      Astepro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7976935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Astelin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10584675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine, Nasal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10584683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8022?source=see_link\">",
"      see \"Azelastine (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Seasonal allergic rhinitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 5-11 years (Astelin&reg;): 1 spray in each nostril twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults (Astelin&reg;, Astepro&reg;): 1-2 sprays in each nostril twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vasomotor rhinitis: Children &ge;12 years and Adults (Astelin&reg;): 2 sprays in each nostril twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7977055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [spray]: 0.1% [137 mcg/spray] (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Astelin&reg;: 0.1% [137 mcg/spray] (30 mL) [contains benzalkonium chloride; 200 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Astepro&reg;: 0.15% [205.5 mcg/spray] (30 mL) [contains benzalkonium chloride; 200 metered sprays]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7976937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10584893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before use, the child-resistant screw cap on the bottle should be replaced with the pump unit and the delivery system should be primed with 4 sprays (Astelin&reg;), 6 sprays (Astepro&reg;), or until a fine mist appears; when 3 or more days have elapsed since the last use, the pump should be reprimed with 2 sprays or until a fine mist appears. Avoid spraying in eyes or mouth.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10584676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of the symptoms of seasonal allergic rhinitis (SAR) and vasomotor rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7976926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Astelin&reg; may be confused with Astepro&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7976972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions may be dose-, indication-, or product-dependent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, anxiety, depersonalization, depression, dizziness, drowsiness, dysesthesia, fatigue, fever, headache, hypoesthesia, malaise, nervousness, sleep disorder, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, eczema, furunculosis, hair and follicle infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, aphthous stomatitis, appetite increased, bitter taste, constipation, diarrhea, gastroenteritis, glossitis, nausea, ulcerative stomatitis, toothache, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Albuminuria, hematuria, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, extremity pain, hyperkinesia, myalgia, rheumatoid arthritis, temporomandibular dislocation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, eye pain, watery eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchitis, bronchospasm, cold symptoms/rhinitis, cough, epistaxis, laryngitis, nasal burning/congestion, nocturnal dyspnea, paroxysmal sneezing , pharyngitis, pharyngolaryngeal pain, postnasal drip, sinus hypersecretion, sinusitis, throat burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, herpes simplex infection, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactoid reaction, atrial fibrillation, blurred vision, chest pain, confusion, facial edema, involuntary muscle contractions, loss of smell, paresthesia, parosmia, rash, tolerance, transaminases increased, urinary retention, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10584677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azelastine or any component",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7976976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7976977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7976963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7976964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have shown toxic effects to the fetus at maternally toxic doses.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10584680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the blood vessels and respiratory tract; reduces hyper-reactivity of the airways; increases the motility of bronchial epithelial cilia, improving mucociliary transport",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10584681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 30 minutes to 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10584682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Metabolized by cytochrome P450 enzyme system; active metabolite desmethylazelastine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: Azelastine: 22 hours; desmethylazelastine: 52 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Clearance: 0.5 L/hour/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10584894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/54/12132?source=see_link\">",
"      see \"Azelastine (nasal): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      McNeely W and Wiseman LR, \"Intranasal Azelastine. A Review of Its Efficacy in the Management of Allergic Rhinitis,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 1988, 56(1):91-114.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15940 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5445=[""].join("\n");
var outline_f5_20_5445=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976934\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976935\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584675\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584683\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977055\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976937\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584893\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584676\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976926\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976972\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584677\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976976\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976977\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976963\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976964\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584680\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584681\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584682\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584894\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15940|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8022?source=related_link\">",
"      Azelastine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/54/12132?source=related_link\">",
"      Azelastine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/47/17139?source=related_link\">",
"      Azelastine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/17/38164?source=related_link\">",
"      Azelastine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31026?source=related_link\">",
"      Azelastine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_20_5446="Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease";
var content_f5_20_5446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5446/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5446/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5446/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5446/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5446/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5446/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/20/5446/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma levels of aspartate and alanine aminotransferases (AST [SGOT] and ALT [SGPT]) are routinely measured to assess liver function. The aminotransferases are normally present in the circulation in low concentrations, usually less than 40 int.",
"    <span class=\"nowrap\">",
"     unit/L.",
"    </span>",
"    Plasma levels of up to 300 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    are nonspecific and may be seen in a number of hepatic diseases. In some cases, elevations in AST and ALT may be the first clue (eg, in the preicteric phase of acute viral hepatitis) or the only clue (eg, in anicteric hepatitis) to the presence of liver disease.",
"   </p>",
"   <p>",
"    An underlying cause of liver disease can be predicted by the medical history and laboratory examination in the vast majority of patients with abnormal tests of liver function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common diagnosis in patients in whom the above is unrevealing is hepatic steatosis or steatohepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general approach to patients with chronic isolated elevations in serum aminotransferases is available elsewhere in UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .) This topic review will focus on four important clinical issues related to the interpretation of serum aminotransferase levels:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Marked elevation in aminotransferase levels",
"     </li>",
"     <li>",
"      The AST-to-ALT ratio",
"     </li>",
"     <li>",
"      High aminotransferase levels in the absence of hepatic disease",
"     </li>",
"     <li>",
"      Normal aminotransferase levels in the presence of hepatic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further detail on the serum aminotransferases and other measures that reflect injury to hepatocytes is also available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=see_link\">",
"     \"Liver biochemical tests that detect injury to hepatocytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SIGNIFICANCE OF MARKEDLY ELEVATED AMINOTRANSFERASE LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the nonspecific nature of mild to moderate aminotransferase elevations, striking increases (exceeding 1000 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    or 50 times the upper limit of normal) are seen in a smaller number of diseases. The most common are acute viral hepatitis, shock liver (ischemic hepatitis), and acute drug- or toxin-induced liver injury (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication). On rare occasions, similar values suggesting acute hepatitis can be seen in a number of other settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      During an acute exacerbation of autoimmune chronic active hepatitis.",
"     </li>",
"     <li>",
"      Spontaneous reactivation of chronic type B hepatitis.",
"     </li>",
"     <li>",
"      Superimposition of delta hepatitis in a chronic carrier of hepatitis B virus infection [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Miscellaneous disorders such as acute Budd-Chiari syndrome (especially those with concomitant portal vein thrombosis), veno-occlusive disease, HELLP syndrome, acute fatty liver of pregnancy, and hepatic infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the aminotransferase levels are almost always below 1000 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    in patients with extrahepatic biliary obstruction and below 500 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    in alcoholic hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the etiology, the height of the aminotransferase elevation does not correlate with the extent of hepatocellular necrosis on liver biopsy and generally has no prognostic value. There is, however, one pattern that is important to recognize: a rapid decrease in plasma AST and ALT levels, together with a rise in the plasma bilirubin concentration and prolongation of the prothrombin time, is indicative of a poor prognosis in patients with acute fulminant hepatitis.",
"   </p>",
"   <p>",
"    In addition, serial determinations of plasma aminotransferase levels can often be used to follow the course of the liver disease. Normalization of plasma levels typically occurs over several weeks to months in patients with acute viral hepatitis or drug- or toxin-induced liver damage. In comparison, patients with shock liver (ischemic hepatitis) may normalize aminotransferase levels within a few days as the hypotension or left ventricle failure is corrected or alleviated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=see_link\">",
"     \"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     AST/ALT ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio is approximately 0.8 in normal subjects. In some settings, this ratio changes in characteristic ways that may suggest a diagnosis. In particular, the AST is greater than the ALT in alcoholic hepatitis and a ratio greater than 2:1 is suggestive of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link&amp;anchor=H418822015#H418822015\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smaller increases in the ratio to values greater than 1.0 occur in other causes of cirrhosis but not in most other liver diseases. In one study, for example, the majority of patients with chronic viral hepatitis had an",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio below 1.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/5\">",
"     5",
"    </a>",
"    ]. Among 100 patients with chronic hepatitis due to hepatitis B virus, the ratio was 0.59 in those without cirrhosis and 1.02 in those with cirrhosis. Furthermore, the ratio often rose to greater than 1.0 when cirrhosis first became apparent. Thus, the authors suggested that an",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio above 1.0 in a patient with non-alcoholic liver disease should suggest the presence of cirrhosis; furthermore, a value above 1.0 in a cirrhotic patient is not necessarily indicative of alcoholic liver disease.",
"   </p>",
"   <p>",
"    Similar findings have been described in hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one study of 139 patients, the mean",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio was higher among patients with cirrhosis than in those without cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/6\">",
"     6",
"    </a>",
"    ]. An",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio &ge;1 had 100 percent specificity and 53 percent sensitivity for cirrhosis using corresponding liver biopsy specimens as the gold standard. The positive and negative predictive values were 100 and 81 percent, respectively. However, two additional series found that the predictive accuracy of this ratio was not as high [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Thus, its clinical utility remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ELEVATION OF AMINOTRANSFERASES IN THE ABSENCE OF LIVER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased levels of AST alone or both AST and ALT in the absence of liver disease can occur in several settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      False positive elevations in the AST have been reported in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      estolate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=see_link\">",
"       para-aminosalicylic acid",
"      </a>",
"      and during diabetic ketoacidosis when AST was measured using a calorimetric assay [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevations in both AST and ALT levels can occur in patients with primary muscle disease in whom liver disease has been excluded by serologic tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      normal liver biopsy. A concurrent increase in creatine phosphokinase (CPK), LDH or aldolase levels suggests a primary muscle source. Their ratio depends in part upon when they are assessed relative to the muscle injury [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/11\">",
"       11",
"      </a>",
"      ]. Immediately after muscle injury, the",
"      <span class=\"nowrap\">",
"       AST/ALT",
"      </span>",
"      ratio is generally greater than three, but approaches one within a few days because of a faster decline in the serum AST. Peak AST and ALT levels are variable. In one series, peak AST levels range from as low as 235 int. unit to as high as 10,000 int. unit while peak ALT levels range from as low as 115 int.",
"      <span class=\"nowrap\">",
"       unit/L",
"      </span>",
"      to as high as 850 int.",
"      <span class=\"nowrap\">",
"       unit/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rare cases have been described of moderate elevations in plasma AST levels due to the presence of macro AST in which AST complexes with immunoglobulin, usually IgG [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/12\">",
"       12",
"      </a>",
"      ]. This finding is analogous to macroamylasemia and often leads to diagnostic confusion.",
"     </li>",
"     <li>",
"      Elevation in serum aminotransferases have been described with hypothyroidism, hyperthyroidism and adrenal insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Low aminotransferase levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Falsely lowered AST values are common in azotemic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/13\">",
"     13",
"    </a>",
"    ]. This phenomenon is most pronounced when the",
"    <span class=\"nowrap\">",
"     SMA-12/60",
"    </span>",
"    autoanalyzer is used and presumably reflects interference with the assay by a retained uremic toxin. AST activity increases significantly after hemodialysis, indicating removal of the inhibitor which does not appear to be urea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33381?source=see_link\">",
"     \"Serum enzymes in patients with renal failure\"",
"    </a>",
"    .) Subnormal values of serum ALT have been described in patients with Crohn's disease, the reason for which is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CELIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations of serum aminotransferases have been observed in patients with subclinical celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In one report, the serum AST ranged from 29 to 80, and the serum ALT ranged from 60 to 130 with the ALT usually slightly greater than AST [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/15\">",
"     15",
"    </a>",
"    ]. Serum aminotransferases returned to normal in all but one patient one year following a gluten free diet. Such patients may have mild to severe liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H31#H31\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NORMAL AMINOTRANSFERASE LEVELS IN THE PRESENCE OF LIVER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminotransferase levels may be normal in a subset of liver disease. In a common disorder, nonalcoholic fatty liver disease, there can be a striking lack of correlation between the height of ALT elevation and histologic damage on liver biopsy. Similar dissociation can occur in patients with chronic viral hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15847?source=see_link\">",
"     \"Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general approach to patients with elevations in serum aminotransferases is available elsewhere in UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are four important clinical issues related to the interpretation of serum aminotransferase levels, which are summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Marked elevation in aminotransferase levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Striking increases (exceeding 1000 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    or 50 times the upper limit of normal) are most commonly seen in acute viral hepatitis, shock liver (ischemic hepatitis), and acute drug- or toxin-induced liver injury (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication). On rare occasions, similar values suggesting acute hepatitis can be seen in a number of other settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      During an acute exacerbation of autoimmune chronic active hepatitis.",
"     </li>",
"     <li>",
"      Spontaneous reactivation of chronic type B hepatitis.",
"     </li>",
"     <li>",
"      Superimposition of delta hepatitis in a chronic carrier of hepatitis B virus infection.",
"     </li>",
"     <li>",
"      Miscellaneous disorders such as acute Budd-Chiari syndrome (especially those with concomitant portal vein thrombosis), veno-occlusive disease, HELLP syndrome, acute fatty liver of pregnancy, and hepatic infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     AST-to-ALT ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aspartate aminotransferase to alanine aminotransferase",
"    <span class=\"nowrap\">",
"     (AST/ALT)",
"    </span>",
"    ratio is approximately 0.8 in normal subjects. In some settings, this ratio changes in characteristic ways that may suggest a diagnosis. In particular, the AST is greater than the ALT in alcoholic hepatitis and a ratio greater than 2:1 is highly suggestive of this disorder. A ratio &gt;1.0 may also suggest the presence of cirrhosis in patients with chronic viral hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Elevated aminotransferase levels without liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions can be associated with elevated aminotransferase levels without liver disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      False positive elevations in the AST in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      estolate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=see_link\">",
"       para-aminosalicylic acid",
"      </a>",
"      and during diabetic ketoacidosis when AST was measured using a calorimetric assay [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary muscle disease in when liver disease has been excluded by serologic tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      normal liver biopsy. A concurrent increase in creatine phosphokinase (CPK), lactate dehydrogenase (LDH), or aldolase levels suggests a primary muscle source.",
"     </li>",
"     <li>",
"      Macro AST, in which AST complexes with immunoglobulin, usually IgG [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5446/abstract/12\">",
"       12",
"      </a>",
"      ]. This rare finding is analogous to macroamylasemia and often leads to diagnostic confusion.",
"     </li>",
"     <li>",
"      Subclinical celiac disease.",
"     </li>",
"     <li>",
"      Hypothyroidism and hyperthyroidism.",
"     </li>",
"     <li>",
"      Adrenal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Normal aminotransferase levels in the presence of liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminotransferase levels may be normal in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemochromatosis",
"     </li>",
"     <li>",
"      Methotrexate- or amiodarone-induced hepatic injury,",
"     </li>",
"     <li>",
"      Chronic hepatitis C virus infection",
"     </li>",
"     <li>",
"      Post-jejunoileal bypass",
"     </li>",
"     <li>",
"      Nonalcoholic fatty liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116258113\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/1\">",
"      Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/2\">",
"      Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94:3010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/3\">",
"      Davis GL, Hoofnagle JH. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med 1985; 102:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/4\">",
"      Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/5\">",
"      Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/6\">",
"      Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/7\">",
"      Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/8\">",
"      Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000; 95:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/9\">",
"      Reedy DW, Loo AT, Levine RA. AST/ALT ratio &gt; or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998; 43:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/10\">",
"      Sabath LD, Gerstein DA, Finland M. Serum glutamic oxalacetic transaminase. False elevations during administration of erythromycin. N Engl J Med 1968; 279:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/11\">",
"      Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005; 41:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/12\">",
"      Litin SC, O'Brien JF, Pruett S, et al. Macroenzyme as a cause of unexplained elevation of aspartate aminotransferase. Mayo Clin Proc 1987; 62:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/13\">",
"      Cohen GA, Goffinet JA, Donabedian RK, Conn HO. Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 1976; 84:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/14\">",
"      Vadstrup S. Subnormal alanine aminotransferase values in blood of patients with Crohn disease. Scand J Gastroenterol 2004; 39:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/15\">",
"      Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/16\">",
"      Volta U, De Franceschi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998; 352:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5446/abstract/17\">",
"      Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004; 2:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3610 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5446=[""].join("\n");
var outline_f5_20_5446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SIGNIFICANCE OF MARKEDLY ELEVATED AMINOTRANSFERASE LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AST/ALT ratio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ELEVATION OF AMINOTRANSFERASES IN THE ABSENCE OF LIVER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Low aminotransferase levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CELIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NORMAL AMINOTRANSFERASE LEVELS IN THE PRESENCE OF LIVER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Marked elevation in aminotransferase levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AST-to-ALT ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Elevated aminotransferase levels without liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Normal aminotransferase levels in the presence of liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116258113\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=related_link\">",
"      Alcoholic hepatitis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15847?source=related_link\">",
"      Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=related_link\">",
"      Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=related_link\">",
"      Liver biochemical tests that detect injury to hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33381?source=related_link\">",
"      Serum enzymes in patients with renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_20_5447="PDA closure Glanturco coils";
var content_f5_20_5447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glanturco coils used to close patent ductus arteriosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gianturco coils have been utilized for percutaneous occlusion of patent arteriosus ductus. Coils come in a variety of sizes. They are usually made of stainless steel and contain fibers to increase their thrombogenicity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Hill, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5447=[""].join("\n");
var outline_f5_20_5447=null;
var title_f5_20_5448="Hyperbaric oxygen therapy";
var content_f5_20_5448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperbaric oxygen therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5448/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5448/contributors\">",
"     C Crawford Mechem, MD, FACEP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5448/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5448/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5448/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5448/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5448/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/20/5448/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen (HBO) serves as primary or adjunctive therapy for a diverse range of medical conditions (",
"    <a class=\"graphic graphic_table graphicRef75304 \" href=\"UTD.htm?11/50/12075\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In the United States, over 500 hyperbaric facilities offer either single occupant (\"monoplace\") or multiple occupant (\"multiplace\") chambers. Information regarding the location of hyperbaric facilities can be accessed through the Undersea &amp; Hyperbaric Medical Society website (",
"    <a class=\"external\" href=\"file://www.uhms.org/\">",
"     www.uhms.org",
"    </a>",
"    ) or via the Divers Alert Network Emergency Hotline (US phone numbers: 919-684-8111 or 919-684-4326; website:",
"    <a class=\"external\" href=\"file://www.diversalertnetwork.org/\">",
"     www.diversalertnetwork.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanisms of action, administration, risks, and outcomes of HBO therapy for its currently accepted indications will be reviewed here. Smoke inhalation, carbon monoxide poisoning, and diving complications are discussed separately in greater detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link\">",
"     \"Complications of scuba diving\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the benefits of HBO are explained by the simple physical relationships determining gas concentration, volume, and pressure. HBO is most commonly used under conditions of tissue hypoxia or to treat decompression sickness or gas embolism, in which gas bubbles obstruct blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased oxygen delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henry's Law states that the amount of an ideal gas dissolved in solution is directly proportional to its partial pressure. Thus, the dissolved plasma oxygen concentration of 0.3",
"    <span class=\"nowrap\">",
"     mL/dL",
"    </span>",
"    at sea level (1.0 atm) increases to 1.5",
"    <span class=\"nowrap\">",
"     mL/dL",
"    </span>",
"    upon administration of 100 percent oxygen, while hyperbaric oxygen delivered at 3.0 atm yields a dissolved oxygen content of 6",
"    <span class=\"nowrap\">",
"     mL/dL.",
"    </span>",
"    The latter figure is sufficient to meet resting tissue oxygen extraction requirements irrespective of the adequacy of the hemoglobin-bound oxygen pool. The ability of HBO to augment oxygen content and independently meet resting tissue oxygen requirements has led to its use in conditions of compromised oxygen delivery, such as profound anemia, carbon monoxide (CO) poisoning, and both acute and chronic ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2,3,6-9\">",
"     2,3,6-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduction of gas bubble size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of hyperbaric oxygen therapy for decompression illness is based upon Boyle's Law, since the volume of nitrogen bubbles is inversely related to the pressure exerted upon it. At 3.0 atm, bubble volume decreases by approximately two-thirds. Further bubble dissolution is accomplished by the replacement of inert nitrogen within the bubbles with oxygen, which is then rapidly metabolized by tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antagonism of carbon monoxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) binds to hemoglobin with an affinity 200 to 250 times as great as that of oxygen (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    ). The presence of carboxyhemoglobin (COHb) results in a leftward shift and hyperbolic shape of the oxyhemoglobin dissociation curve, corresponding to a marked decrease in oxygen-carrying capacity and in tissue oxygen release (",
"    <a class=\"graphic graphic_figure graphicRef50058 \" href=\"UTD.htm?27/34/28207\">",
"     figure 1",
"    </a>",
"    ). The four to six hour half-life of COHb at ambient air decreases to 40 to 80 minutes with 100 percent normobaric oxygen (NBO). With HBO therapy, the half-life of COHb decreases further to 15 to 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Improved wound healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro, HBO modulates local and systemic effects found in both acute and chronic injury, ischemia, and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Many of its effects are mediated by reactive oxygen species (eg, oxygen-derived free radicals,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , hypochlorous acid) and reactive nitrogen species (eg, nitric oxide), which are generated in tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/15\">",
"     15",
"    </a>",
"    ]. Local hyperoxia induces vasoconstriction and reduces vasogenic edema following acute trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/12\">",
"     12",
"    </a>",
"    ]. HBO ameliorates ischemia-reperfusion-induced leukocyte influx [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/13\">",
"     13",
"    </a>",
"    ]. By altering conditions of local hypoxia, HBO facilitates fibroblast proliferation, angiogenesis, and wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/6,16,17\">",
"     6,16,17",
"    </a>",
"    ]. HBO augments neutrophil bactericidal activity, limits clostridial exotoxin and spore production, kills anaerobes such as Clostridium perfringens, and inhibits the growth of several other bacterial pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2,17-20\">",
"     2,17-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiplace chambers allow closer monitoring of critically ill patients, while single occupancy chambers are most appropriate for the treatment of chronic medical conditions in stable patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/3\">",
"     3",
"    </a>",
"    ]. Chamber pressure is usually maintained between 2.5 and 3.0 atm, with treatment lasting 45 to 300 minutes depending upon the indication. Acute therapy may require only one or two treatments, while chronic medical conditions may warrant up to 30 or more sessions. Typically, hyperbaric therapy is administered with pressurized oxygen or air. Pressures exceeding 2.8 to 3.0 atm, particularly over prolonged exposure hyperbaric periods, dramatically increase the risk of both neurologic and pulmonary oxygen toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Helium/oxygen",
"    </span>",
"    (heliox) or",
"    <span class=\"nowrap\">",
"     nitrogen/oxygen",
"    </span>",
"    (nitrox) mixtures are indicated only in certain instances of decompression illness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"     \"Oxygen toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only absolute contraindication to HBO therapy is untreated pneumothorax. Relative contraindications include obstructive lung disease, upper respiratory or sinus infections, recent ear surgery or injury, fever, and claustrophobia. Pregnancy was once believed to represent a contraindication to HBO, but now is considered an impetus to pursue HBO therapy among patients with CO intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/11\">",
"     11",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    ). Patients with a history of a seizure disorder, pneumothorax, or chest surgery are at highest risk for complications related to barotrauma or central nervous system oxygen toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric therapy is generally safe and well tolerated. Most side effects are mild and reversible, although severe consequences can occur in rare cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reversible myopia due to direct oxygen toxicity to the lens is the most common side effect of HBO and occurs in up to 20 percent of patients; weeks to months may be required for complete recovery.",
"     </li>",
"     <li>",
"      Symptomatic otic barotrauma occurs in up to 3 to 20 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/3,24\">",
"       3,24",
"      </a>",
"      ] and is more common in patients undergoing multiple treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"       \"Ear barotrauma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Middle ear effusions (which may be hemorrhagic) and tympanic membrane rupture occur infrequently. Middle ear symptoms preclude repeat therapy in less than 1 percent of patients; they may be alleviated by the placement of tympanostomy tubes [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link\">",
"       \"Acute otitis media in adults (suppurative and serous)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary barotrauma is unusual, provided any pneumothoraces have been identified and decompressed before initiating HBO [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary oxygen toxicity, manifested by chest tightness, cough, and a reversible decline of pulmonary function, occurs most commonly in patients receiving multiple treatments or previously exposed to high oxygen levels [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"       \"Oxygen toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures due to central nervous system oxygen toxicity are a rare but dramatic consequence of HBO treatment; estimates of incidence range from 1 in 11,000 to 2.4 per 100,000 treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/23,26,28\">",
"       23,26,28",
"      </a>",
"      ]. The risk is increased by HBO exposure greater than 90 to 120 minutes and by pressures greater than 2.8 to 3.0 atm. Patients receiving glucocorticoids, insulin, thyroid replacement, and sympathomimetic medications may be at higher risk of central nervous system oxygen toxicity. HBO has been associated with hypoglycemia in some patients with diabetes, and hypoglycemia should therefore be considered in the differential diagnosis of HBO-associated seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/17\">",
"       17",
"      </a>",
"      ]. Seizures due to oxygen toxicity do not typically result in permanent structural brain damage [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Seizures should be managed acutely by reducing the inspired oxygen concentration to that of air (FIO2 = 0.21), administering anticonvulsant therapy, and, if necessary, terminating hyperbaric treatment. Oxygen toxicity may be prevented by alternating between short (five minute) intervals of air and longer intervals (30 minutes) of 100 percent oxygen, to limit oxygen free radical formation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/3\">",
"       3",
"      </a>",
"      ]. Patients in monoplace chambers should have therapy terminated, as airway management and monitoring are compromised. The need for further treatment with lower FIO2 should be addressed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link&amp;anchor=H33#H33\">",
"       \"Status epilepticus in adults\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decompression sickness may occur in patients breathing compressed air that contains nitrogen. The likelihood of decompression sickness is reduced by administration of 100 percent oxygen toward the end of the treatment period and by adherence to standard US Navy guidelines governing gradual decompression [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/17\">",
"       17",
"      </a>",
"      ]. Decompression sickness does",
"      <strong>",
"       not",
"      </strong>",
"      occur in patients breathing 100 percent oxygen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen (HBO) serves as primary or adjunctive therapy for a diverse range of medical conditions (",
"    <a class=\"graphic graphic_table graphicRef75304 \" href=\"UTD.htm?11/50/12075\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Carbon monoxide or cyanide poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) poisoning is a leading cause of death from poisoning. HBO reduces the half-life of carboxyhemoglobin, an observation that has led to the study of HBO for preventing the late neurocognitive deficits associated with severe CO poisoning. The role of HBO in the treatment of CO and cyanide poisoning is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link&amp;anchor=H12#H12\">",
"     \"Carbon monoxide poisoning\", section on 'Hyperbaric oxygen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link&amp;anchor=H6019904#H6019904\">",
"     \"Cyanide poisoning\", section on 'Hyperbaric oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Decompression sickness and air embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Divers breathing compressed air who return to the surface too rapidly, and aviators ascending over 5500 meters are at risk for decompression sickness and arterial gas embolism. Those with a patent foramen ovale are at increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/29\">",
"     29",
"    </a>",
"    ]. Bubble formation in tissues or in blood occurs as the partial pressure of inert gas (mostly nitrogen) exceeds that of ambient air. The obstruction of vessels and lymphatics by bubbles is accompanied by the activation of leukocytes, endothelial damage, and resultant alterations in capillary permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decompression sickness manifests a range of severity from self-limited rash or joint pain to focal neurologic deficits, paralysis, seizures, hypovolemic shock, and death. Patients typically develop symptoms within several hours of ascent, with rapid onset and severe symptoms implying a more ominous course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of scuba diving\", section on 'Decompression sickness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arterial and venous gas embolism may arise as a consequence of pulmonary overinflation and subsequent alveolar rupture. Such emboli occur during uncontrolled ascent while diving or during mechanical ventilation. Alternatively, air directly introduced through a variety of means, including central venous catheter placement, cardiac, neurologic, and otolaryngological surgery, may yield venous and arterial emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HBO is the primary treatment for decompression sickness and arterial gas embolism. It is unclear whether the efficacy of HBO is due primarily to decreased bubble size and relief of local hypoxia, or to modulation of the pathologic effects mediated by bubbles in tissue and in vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Patients should initiate HBO treatment as soon as possible, because a sharp decrease in the successful treatment of cerebral air emboli has been noted after a four to five hour delay [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment consists of a two to five hour session at 2.5 to 3.0 atm, until symptoms abate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/21\">",
"     21",
"    </a>",
"    ]. Adjunctive treatment with glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or a combination of prostacyclin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been reported, but the efficacy of these interventions is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Patients with residual deficits should receive repetitive, intermittent hyperbaric treatments and may require several days to reach maximum improvement. Some patients suffer neurologic deterioration after seemingly successful recompression treatment. This phenomenon may be due to the slow reexpansion of residual gas bubbles upon termination of hyperbaric therapy, postischemic reperfusion injury, or re-embolization from an underlying pulmonary abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute traumatic or thermal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBO has been recommended as adjunctive therapy for a range of acute traumatic and ischemic syndromes, including crush injuries, compartment syndromes, and situations of vascular compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Animal models of ischemia and compartment syndromes suggest that the benefit of HBO may be due to a combination of increased tissue oxygenation, reduced edema through hyperoxia-induced vasospasm, protection from reperfusion injury and secondary ischemia, and antimicrobial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/6,12,34-36\">",
"     6,12,34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of this approach was evaluated in a trial in which 36 patients with crush injuries were randomly assigned to either a 90 minute twice daily HBO treatment or a 90 minute twice daily sham treatment consisting of NBO administered within a hyperbaric chamber for a total of six days and begun within 24 hours of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/37\">",
"     37",
"    </a>",
"    ]. The group treated with HBO had significantly more complete healing (17 versus 10 patients) and required fewer skin flaps, grafts, vascular surgery, or amputation (1 versus 6 patients).",
"   </p>",
"   <p>",
"    In contrast, a randomized prospective trial evaluating adjunctive HBO in 125 burn victims failed to demonstrate any benefit in mortality, length of stay, or the extent of autografting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/38\">",
"     38",
"    </a>",
"    ]. A subsequent systematic review found only two high quality trials designed to asses this question, including the one described above, and concluded that there was insufficient evidence to support the use of HBO following thermal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiation injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously irradiated tissue is characterized by fibro-atrophic changes, with decreased vascularity, impaired cellular proliferation, and local hypoxia that can persist long after radiation therapy. Subsequent injury (eg, dental extraction) or surgical manipulation may lead to soft tissue radionecrosis and osteoradionecrosis, manifested by edema, ulceration, poor wound healing, and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/16,17,40\">",
"     16,17,40",
"    </a>",
"    ]. The value of HBO has been studied in patients with laryngeal, oropharyngeal, and other head and neck cancers who develop osteoradionecrosis following radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2\">",
"     2",
"    </a>",
"    ]. In theory, HBO has the potential to improve this condition because of its impact on collagen synthesis and vascular density. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822453#H3822453\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Osteoradionecrosis and soft tissue necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, the available data are conflicting, and the benefit of HBO to prevent or treat established osteoradionecrosis of the jaw in irradiated patients with head and neck cancer is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822453#H3822453\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Osteoradionecrosis and soft tissue necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies suggest that HBO may reduce soft tissue radionecrosis and improve reconstructive outcome in patients who have received chest, pelvic, perineal, or extremity irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/42-50\">",
"     42-50",
"    </a>",
"    ]. Furthermore, a Cochrane Collaboration review suggested that HBO may be of benefit for patients with late radiation tissue injury to the head, neck, anus, and rectum, and to promote healing of irradiated sockets after dental extraction. There was no benefit for neural tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/51\">",
"     51",
"    </a>",
"    ]; however, randomized trials have not been conducted, and questions persist regarding the ultimate benefit of this approach.",
"   </p>",
"   <p>",
"    Protocols for prevention and treatment of osteoradionecrosis and soft tissue radionecrosis generally have included 20 to 30 preoperative HBO sessions at 2.4 atm delivered over 90 minutes, followed by 10 postoperative treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary treatment regimen for aggressive soft tissue infections such as clostridial myonecrosis (gas gangrene), necrotizing fasciitis, and Fournier's gangrene consists of antibiotic therapy and aggressive debridement. A number of retrospective and observational studies have evaluated the role of HBO as an adjunctive therapy for severe, life- or limb-threatening necrotizing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/52-57\">",
"     52-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although no randomized, controlled trials in humans have been conducted, a rigorous study evaluating combinations of antibiotics, surgery, and HBO for clostridial infection in a dog model has demonstrated a 35 percent survival increase with adjunctive HBO [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/58\">",
"     58",
"    </a>",
"    ]. In patients with clostridial myonecrosis, HBO may reduce mortality and better define necrotic tissue, facilitating more precise amputation and debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjunctive HBO may decrease mortality and limit the extent of debridement in Fournier's gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/53,54\">",
"     53,54",
"    </a>",
"    ] and necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/55-57,59\">",
"     55-57,59",
"    </a>",
"    ]. A retrospective review using a nationwide database from Singapore (Nationwide Inpatient Sample) identified 45,913 cases of necrotizing soft tissue infection and reported a statistically significant reduction in mortality among those patients (n = 405) treated with HBO (4.5 versus 9.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/59\">",
"     59",
"    </a>",
"    ]. This advantage persisted after controlling for other predictors of mortality and possible confounders (OR 0.49; 95% CI 0.29-0.83).",
"   </p>",
"   <p>",
"    Smaller studies, also retrospective, have reported conflicting results. One observational study of 26 patients with Fournier's gangrene found a significantly lower mortality rate among HBO-treated patients (7 versus 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/54\">",
"     54",
"    </a>",
"    ]. A second observational study of 29 patients with necrotizing fasciitis noted significantly fewer debridements and a lower mortality rate (23 versus 66 percent) when HBO was employed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/57\">",
"     57",
"    </a>",
"    ]. In contrast, a subsequent study of 42 patients with Fournier's gangrene suggested increased mortality, morbidity, and cost of therapy among patients treated with HBO [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HBO has been advocated for use in other severe invasive infections such as cutaneous soft-tissue and rhinocerebral mucormycosis (or zygomycosis) and actinomycotic brain abscesses, although data in support of these indications are less robust [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/20,61\">",
"     20,61",
"    </a>",
"    ]. HBO also has been advocated for therapy of refractory osteomyelitis, although few controlled studies have been performed to confirm its efficacy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When used to treat acute infections, HBO should be implemented early, with two to three daily 90 minute HBO sessions at 3 atm. These high pressures maintain tissue oxygen tension above 300 mmHg (sufficient to inhibit clostridial spore and exotoxin production) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nonhealing ulcers, skin grafts, and wound healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBO has been used as an adjunct therapy in the treatment of nonhealing wounds, compromised skin grafts, and other wounds. The use of HBO for these indications is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H369375086#H369375086\">",
"     \"Basic principles of wound management\", section on 'Hyperbaric oxygen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of potential HBO uses remain poorly validated and require more rigorous evaluation. Future indications for HBO may be derived from its apparent modulation of ischemia-reperfusion injury and inflammation. Preliminary animal and human studies evaluating uses in syndromes as disparate as myocardial infarction, the systemic inflammatory response syndrome, traumatic brain or spinal cord injury, sickle cell crisis, fibromyalgia, and acute stroke have been conducted, with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5448/abstract/1,14,63-67\">",
"     1,14,63-67",
"    </a>",
"    ]. Further investigation will need to be conducted before HBO can be endorsed for these potential indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon clinical experience and the data detailed above, hyperbaric oxygen (HBO) is a reasonable therapy in the following circumstances:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe decompression sickness or arterial gas embolism.",
"     </li>",
"     <li>",
"      Significant cases of carbon monoxide poisoning. HBO for this indication is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HBO may be useful in the care of patients with severe anemia, actinomycotic brain abscesses, acute crush injuries, prior radiation therapy, aggressive soft tissue infections, nonhealing ulcers, or compromised skin grafts and flaps. Further research is required in these situations in order to confirm the benefits of HBO and justify its significant costs and potential risks.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/1\">",
"      Gill AL, Bell CN. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM 2004; 97:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/2\">",
"      Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996; 334:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/3\">",
"      Leach RM, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ 1998; 317:1140.",
"     </a>",
"    </li>",
"    <li>",
"     Undersea &amp; Hyperbaric Medical Society. www.uhms.org (Accessed on August 09, 2005).",
"    </li>",
"    <li>",
"     Medicare Coverage Issues Manual. Publication no. HCFA-Pub6 Transmittal 129, Department of Health and Human Services (DHHS), Health Care Financing Administration (HCFA), 2000. www.cms.hhs.gov/manuals/pm_trans/R129CIM.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/6\">",
"      Wattel F, Mathieu D, Nevi&egrave;re R, Bocquillon N. Acute peripheral ischaemia and compartment syndromes: a role for hyperbaric oxygenation. Anaesthesia 1998; 53 Suppl 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/7\">",
"      Hart, GB, Lennon, PA, Strauss, MB. Hyperbaric oxygen in exceptional blood-loss anemia. J Hyperb Med 1987; 2:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/8\">",
"      McLoughlin PL, Cope TM, Harrison JC. Hyperbaric oxygen therapy in the management of severe acute anaemia in a Jehovah's witness. Anaesthesia 1999; 54:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/9\">",
"      Van Meter KW. A systematic review of the application of hyperbaric oxygen in the treatment of severe anemia: an evidence-based approach. Undersea Hyperb Med 2005; 32:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/10\">",
"      PACE N, STRAJMAN E, WALKER EL. Acceleration of carbon monoxide elimination in man by high pressure oxygen. Science 1950; 111:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/11\">",
"      Ernst A, Zibrak JD. Carbon monoxide poisoning. N Engl J Med 1998; 339:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/12\">",
"      Nylander G, Lewis D, Nordstr&ouml;m H, Larsson J. Reduction of postischemic edema with hyperbaric oxygen. Plast Reconstr Surg 1985; 76:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/13\">",
"      Zamboni WA, Wong HP, Stephenson LL. Effect of hyperbaric oxygen on neutrophil concentration and pulmonary sequestration in reperfusion injury. Arch Surg 1996; 131:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/14\">",
"      Luongo C, Imperatore F, Cuzzocrea S, et al. Effects of hyperbaric oxygen exposure on a zymosan-induced shock model. Crit Care Med 1998; 26:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/15\">",
"      Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg 2011; 127 Suppl 1:131S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/16\">",
"      Marx RE, Ehler WJ, Tayapongsak P, Pierce LW. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg 1990; 160:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/17\">",
"      Roth RN, Weiss LD. Hyperbaric oxygen and wound healing. Clin Dermatol 1994; 12:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/18\">",
"      Kaye D. Effect of hyperbaric oxygen on Clostridia in vitro and in vivo. Proc Soc Exp Biol Med 1967; 124:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/19\">",
"      Hill GB, Osterhout S. Experimental effects of hyperbaric oxgen on selected clostridial species. I. In-vitro studies. J Infect Dis 1972; 125:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/20\">",
"      Mader JT, Brown GL, Guckian JC, et al. A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. J Infect Dis 1980; 142:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/21\">",
"      Moon RE, Sheffield PJ. Guidelines for treatment of decompression illness. Aviat Space Environ Med 1997; 68:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/22\">",
"      Shupak A, Melamed Y, Ramon Y, et al. Helium and oxygen treatment of severe air-diving-induced neurologic decompression sickness. Arch Neurol 1997; 54:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/23\">",
"      Plafki C, Peters P, Almeling M, et al. Complications and side effects of hyperbaric oxygen therapy. Aviat Space Environ Med 2000; 71:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/24\">",
"      Fitzpatrick DT, Franck BA, Mason KT, Shannon SG. Risk factors for symptomatic otic and sinus barotrauma in a multiplace hyperbaric chamber. Undersea Hyperb Med 1999; 26:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/25\">",
"      Bessereau J, Tabah A, Genotelle N, et al. Middle-ear barotrauma after hyperbaric oxygen therapy. Undersea Hyperb Med 2010; 37:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/26\">",
"      Davis, JC. Hyperbaric oxygen therapy. J Intensive Care Med 1989; 4:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/27\">",
"      Clements KS, Vrabec JT, Mader JT. Complications of tympanostomy tubes inserted for facilitation of hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg 1998; 124:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/28\">",
"      Yildiz S, Aktas S, Cimsit M, et al. Seizure incidence in 80,000 patient treatments with hyperbaric oxygen. Aviat Space Environ Med 2004; 75:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/29\">",
"      Germonpr&eacute; P. Patent foramen ovale and diving. Cardiol Clin 2005; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/30\">",
"      Leitch DR, Green RD. Pulmonary barotrauma in divers and the treatment of cerebral arterial gas embolism. Aviat Space Environ Med 1986; 57:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/31\">",
"      Murphy BP, Harford FJ, Cramer FS. Cerebral air embolism resulting from invasive medical procedures. Treatment with hyperbaric oxygen. Ann Surg 1985; 201:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/32\">",
"      Evans DE, Catron PW, McDermott JJ, et al. Effect of lidocaine after experimental cerebral ischemia induced by air embolism. J Neurosurg 1989; 70:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/33\">",
"      Hallenbeck JM, Leitch DR, Dutka AJ, et al. Prostaglandin I2, indomethacin, and heparin promote postischemic neuronal recovery in dogs. Ann Neurol 1982; 12:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/34\">",
"      Uhl E, Sirsj&ouml; A, Haapaniemi T, et al. Hyperbaric oxygen improves wound healing in normal and ischemic skin tissue. Plast Reconstr Surg 1994; 93:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/35\">",
"      Kolski JM, Mazolewski PJ, Stephenson LL, et al. Effect of hyperbaric oxygen therapy on testicular ischemia-reperfusion injury. J Urol 1998; 160:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/36\">",
"      Greensmith JE. Hyperbaric oxygen therapy in extremity trauma. J Am Acad Orthop Surg 2004; 12:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/37\">",
"      Bouachour G, Cronier P, Gouello JP, et al. Hyperbaric oxygen therapy in the management of crush injuries: a randomized double-blind placebo-controlled clinical trial. J Trauma 1996; 41:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/38\">",
"      Brannen, AL, Still, J, Haynes, MS, et al. A randomized prospective trial of hyperbaric oxygen in a referral burn center population (abstract). Undersea Hyperb Med 1995; 22:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/39\">",
"      Villanueva E, Bennett MH, Wasiak J, Lehm JP. Hyperbaric oxygen therapy for thermal burns. Cochrane Database Syst Rev 2004; :CD004727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/40\">",
"      Mustoe TA, Porras-Reyes BH. Modulation of wound healing response in chronic irradiated tissues. Clin Plast Surg 1993; 20:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/41\">",
"      Spiegelberg L, Djasim UM, van Neck HW, et al. Hyperbaric oxygen therapy in the management of radiation-induced injury in the head and neck region: a review of the literature. J Oral Maxillofac Surg 2010; 68:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/42\">",
"      Feldmeier JJ, Heimbach RD, Davolt DA, et al. Hyperbaric oxygen as an adjunctive treatment for delayed radiation injury of the chest wall: a retrospective review of twenty-three cases. Undersea Hyperb Med 1995; 22:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/43\">",
"      Feldmeier JJ, Heimbach RD, Davolt DA, et al. Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis. Undersea Hyperb Med 1996; 23:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/44\">",
"      Feldmeier JJ, Heimbach RD, Davolt DA, et al. Hyperbaric oxygen in the treatment of delayed radiation injuries of the extremities. Undersea Hyperb Med 2000; 27:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/45\">",
"      Carl UM, Feldmeier JJ, Schmitt G, Hartmann KA. Hyperbaric oxygen therapy for late sequelae in women receiving radiation after breast-conserving surgery. Int J Radiat Oncol Biol Phys 2001; 49:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/46\">",
"      Bui QC, Lieber M, Withers HR, et al. The efficacy of hyperbaric oxygen therapy in the treatment of radiation-induced late side effects. Int J Radiat Oncol Biol Phys 2004; 60:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/47\">",
"      Gothard L, Stanton A, MacLaren J, et al. Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. Radiother Oncol 2004; 70:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/48\">",
"      Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev 2003; :CD003750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/49\">",
"      Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med 2002; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/50\">",
"      Mayer R, Klemen H, Quehenberger F, et al. Hyperbaric oxygen--an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol 2001; 61:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/51\">",
"      Bennett MH, Feldmeier J, Hampson N, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev 2005; :CD005005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/52\">",
"      Wilkinson D, Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg 2004; 139:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/53\">",
"      Pizzorno R, Bonini F, Donelli A, et al. Hyperbaric oxygen therapy in the treatment of Fournier's disease in 11 male patients. J Urol 1997; 158:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/54\">",
"      Hollabaugh RS Jr, Dmochowski RR, Hickerson WL, Cox CE. Fournier's gangrene: therapeutic impact of hyperbaric oxygen. Plast Reconstr Surg 1998; 101:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/55\">",
"      Green RJ, Dafoe DC, Raffin TA. Necrotizing fasciitis. Chest 1996; 110:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/56\">",
"      Brown DR, Davis NL, Lepawsky M, et al. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg 1994; 167:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/57\">",
"      Riseman JA, Zamboni WA, Curtis A, et al. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 1990; 108:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/58\">",
"      Demello FJ, Haglin JJ, Hitchcock CR. Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen. Surgery 1973; 73:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/59\">",
"      Soh CR, Pietrobon R, Freiberger JJ, et al. Hyperbaric oxygen therapy in necrotising soft tissue infections: a study of patients in the United States Nationwide Inpatient Sample. Intensive Care Med 2012; 38:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/60\">",
"      Mindrup SR, Kealey GP, Fallon B. Hyperbaric oxygen for the treatment of fournier's gangrene. J Urol 2005; 173:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/61\">",
"      Bentur Y, Shupak A, Ramon Y, et al. Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus. Plast Reconstr Surg 1998; 102:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/62\">",
"      Esterhai JL Jr, Pisarello J, Brighton CT, et al. Adjunctive hyperbaric oxygen therapy in the treatment of chronic refractory osteomyelitis. J Trauma 1987; 27:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/63\">",
"      Sharifi M, Fares W, Abdel-Karim I, et al. Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. Am J Cardiol 2004; 93:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/64\">",
"      Stavitsky Y, Shandling AH, Ellestad MH, et al. Hyperbaric oxygen and thrombolysis in myocardial infarction: the 'HOT MI' randomized multicenter study. Cardiology 1998; 90:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/65\">",
"      Rusyniak DE, Kirk MA, May JD, et al. Hyperbaric oxygen therapy in acute ischemic stroke: results of the Hyperbaric Oxygen in Acute Ischemic Stroke Trial Pilot Study. Stroke 2003; 34:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/66\">",
"      Yildiz S, Kiralp MZ, Akin A, et al. A new treatment modality for fibromyalgia syndrome: hyperbaric oxygen therapy. J Int Med Res 2004; 32:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5448/abstract/67\">",
"      Bennett MH, Lehm JP, Jepson N. Hyperbaric oxygen therapy for acute coronary syndrome. Cochrane Database Syst Rev 2011; :CD004818.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 326 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5448=[""].join("\n");
var outline_f5_20_5448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduction of gas bubble size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antagonism of carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Improved wound healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Carbon monoxide or cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Decompression sickness and air embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute traumatic or thermal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiation injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nonhealing ulcers, skin grafts, and wound healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/326|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/34/28207\" title=\"figure 1\">",
"      Effect of carbon monoxide on oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/326|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/50/12075\" title=\"table 1\">",
"      Therapeutic roles for hyperbaric oxygen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=related_link\">",
"      Cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_20_5449="Pathophysiology of sepsis";
var content_f5_20_5449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of sepsis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5449/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5449/contributors\">",
"     Remi Neviere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5449/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5449/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5449/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5449/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/20/5449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal host response to infection is a complex process that localizes and controls bacterial invasion, while initiating the repair of injured tissue. It involves the activation of circulating and fixed phagocytic cells, as well as the generation of proinflammatory and antiinflammatory mediators. Sepsis results when the response to infection becomes generalized and involves normal tissues remote from the site of injury or infection.",
"   </p>",
"   <p>",
"    The pathophysiology of sepsis and mechanisms of multiple organ system dysfunction are reviewed here. The definition and management of sepsis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5444041\">",
"    <span class=\"h1\">",
"     NORMAL RESPONSE TO INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The host response to an infection is initiated when innate immune cells, particularly macrophages, recognize and bind to microbial components. This may occur by several pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pattern recognition receptors (PRRs) on the surface of host immune cells may recognize and bind to the pathogen-associated molecular patterns (PAMPs) of microorganisms [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/1\">",
"       1",
"      </a>",
"      ]. There are three families of PRRs: toll-like receptors (TLRs), nucleotide-oligomerization domain (NOD) leucine-rich repeat proteins, and retinoic-acid-inducible gene I (RIG-I)-like helicases. Examples include the peptidoglycan of Gram-positive bacteria binding to TLR-2 on host immune cells, as well as the lipopolysaccharide of Gram-negative bacteria binding to TLR-4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lipopolysaccharide-binding protein (CD14 complex) on host immune cells.",
"     </li>",
"     <li>",
"      The triggering receptor expressed on myeloid cell (TREM-1) and the myeloid DAP12-associating lectin (MDL-1) receptors on host immune cells may recognize and bind to microbial components [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The binding of immune cell surface receptors to microbial components has multiple effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The engagement of TLRs elicits a signaling cascade via the activation of cytosolic nuclear factor-kb (NF-kb). Activated NF-kb moves from the cytoplasm to the nucleus, binds to transcription sites, and induces activation of a large set of genes involved in the host inflammatory response, such as proinflammatory cytokines (tumor necrosis factor alpha [TNFa], interleukin-1 [IL-1]), chemokines (intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1]), and nitric oxide.",
"     </li>",
"     <li>",
"      Polymorphonuclear leukocytes (PMNs) become activated and express adhesion molecules that cause their aggregation and margination to the vascular endothelium. This is facilitated by the endothelium expressing adherence molecules to attract leukocytes. The PMNs then go through a series of steps (rolling, adhesion, diapedesis, and chemotaxis) to migrate to the site of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/3\">",
"       3",
"      </a>",
"      ]. The release of mediators by PMNs at the site of infection is responsible for the cardinal signs of local inflammation: warmth and erythema due to local vasodilation and hyperemia, and protein-rich edema due to increased microvascular permeability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This process is highly regulated by a mixture of proinflammatory and antiinflammatory mediators secreted by macrophages, which have been triggered and activated by the invasion of tissue by bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proinflammatory mediators &ndash; Important proinflammatory cytokines include tumor necrosis factor-alpha (TNFa) and interleukin-1 (IL-1), which share a remarkable array of biological effects (",
"      <a class=\"graphic graphic_table graphicRef72271 \" href=\"UTD.htm?9/46/9963\">",
"       table 1",
"      </a>",
"      ). The release of TNFa is self-sustaining (ie, autocrine secretion), while non-TNF cytokines and mediators (eg, Il-1, IL-2, IL-6, IL-8, IL-10, platelet activating factor, interferon, and eicosanoids) increase the levels of other mediators (ie, paracrine secretion). The proinflammatory milieu leads to the recruitment of more PMNs and macrophages.",
"     </li>",
"     <li>",
"      Antiinflammatory mediators &ndash; Cytokines that inhibit the production of TNFa and IL-1 are considered antiinflammatory cytokines. Such antiinflammatory mediators suppress the immune system by inhibiting cytokine production by mononuclear cells and monocyte-dependent T helper cells. However, their effects may not be universally antiinflammatory. As examples, IL-10 and IL-6 both enhance B cell function (proliferation, immunoglobulin secretion) and encourage the development of cytotoxic T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The balance of proinflammatory and antiinflammatory mediators regulates the inflammatory processes, including adherence, chemotaxis, phagocytosis of invading bacteria, bacterial killing, and phagocytosis of debris from injured tissue. If the mediators balance each other and the initial infectious insult is overcome, homeostasis will be restored [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/8\">",
"     8",
"    </a>",
"    ]. The end result will be tissue repair and healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1300788\">",
"    <span class=\"h1\">",
"     TRANSITION TO SEPSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis occurs when the release of proinflammatory mediators in response to an infection exceeds the boundaries of the local environment, leading to a more generalized response (",
"    <a class=\"graphic graphic_algorithm graphicRef59298 \" href=\"UTD.htm?40/51/41789\">",
"     algorithm 1",
"    </a>",
"    ). When a similar process occurs in response to a noninfectious condition (eg, pancreatitis, trauma), the process is referred to as systemic inflammatory response syndrome (SIRS). The focus of our review is on sepsis, but much of our discussion is applicable to SIRS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sepsis can be conceptualized as malignant intravascular inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malignant because it is uncontrolled, unregulated, and self-sustaining",
"     </li>",
"     <li>",
"      Intravascular because the blood spreads mediators that are usually confined to cell-to-cell interactions within the interstitial space",
"     </li>",
"     <li>",
"      Inflammatory because all characteristics of the septic response are exaggerations of the normal inflammatory response",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is uncertain why immune responses that usually remain localized sometimes spread beyond the local environment causing sepsis. The cause is likely multifactorial and may include the direct effects of the invading microorganisms or their toxic products, release of large quantities of proinflammatory mediators, and complement activation. In addition, some individuals may be genetically susceptible to developing sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1301093\">",
"    <span class=\"h2\">",
"     Effects of microorganisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial cell wall components (endotoxin, peptidoglycan, muramyl dipeptide, and lipoteichoic acid) and bacterial products (staphylococcal enterotoxin B, toxic shock syndrome toxin-1, Pseudomonas exotoxin A, and M protein of hemolytic group A streptococci) may contribute to the progression of a local infection to sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/10\">",
"     10",
"    </a>",
"    ]. This is supported by the following observations regarding endotoxin, a lipopolysaccharide found in the cell wall of gram negative bacteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endotoxin is detectable in the blood of septic patients.",
"     </li>",
"     <li>",
"      Elevated plasma levels of endotoxin are associated with shock and multiple organ dysfunction (",
"      <a class=\"graphic graphic_table graphicRef50095 \" href=\"UTD.htm?23/58/24492\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Endotoxin reproduces many of the features of sepsis when it is infused into humans, including activation of the complement, coagulation, and fibrinolytic systems [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. These effects may lead to microvascular thrombosis and the production of vasoactive products, such as bradykinin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1300875\">",
"    <span class=\"h2\">",
"     Excess proinflammatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large quantities of proinflammatory cytokines released in patients with sepsis may spill into the bloodstream, contributing to the progression of a local infection to sepsis. These include tumor necrosis factor-alpha (TNFa) and interleukin-1 (IL-1), whose plasma levels peak early and eventually decrease to undetectable levels. Both cytokines can cause fever, hypotension, leukocytosis, induction of other proinflammatory cytokines, and the simultaneous activation of coagulation and fibrinolysis (",
"    <a class=\"graphic graphic_table graphicRef72271 \" href=\"UTD.htm?9/46/9963\">",
"     table 1",
"    </a>",
"    ). The evidence indicating that TNFa has an important role in sepsis is particularly strong. It includes the following: circulating levels of TNFa are higher in septic patients than non-septic patients with shock [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/13\">",
"     13",
"    </a>",
"    ], infusion of TNFa produces symptoms similar to those observed in septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/14\">",
"     14",
"    </a>",
"    ], and anti-TNFa antibodies protect animals from lethal challenge with endotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/15\">",
"     15",
"    </a>",
"    ]. The high levels of TNFa in sepsis are due in part to the binding of endotoxin to lipopolysaccharide (LPS)-binding protein and its subsequent transfer to CD14 on macrophages, which stimulates TNFa release [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complement activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement system is a protein cascade that helps clear pathogens from an organism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. It is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    .) There is evidence that activation of the complement system plays an important role in sepsis; most notably, inhibition of the complement cascade decreases inflammation and improves mortality in animal models:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a rodent model of sepsis, a complement fragment 5a receptor (C5aR) antagonist decreased mortality, inflammation, and vascular permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. In contrast, increased production of complement fragment 5a (C5a) and increased expression of C5aR enhanced neutrophil trafficking [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In several animal models of sepsis (lipopolysaccharide injection in mice and rats, Escherichia coli infusion in dogs and baboons, and cecal ligation and puncture in mice), a complement fragment 1 (C1) inhibitor decreased mortality, inflammation, and vascular permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/23-27\">",
"       23-27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1302244\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single nucleotide polymorphism (SNP) is the most common form of genetic variation. SNPs are stable substitutions of a single base that have a frequency of more than one percent in at least one population and are strewn throughout the genome, including promoters and intergenic regions. At most, only 2 to 3 percent alter the function or expression of a gene. The total number of common SNPs in the human genome is estimated to be more than 10 million. SNPs are used as genetic markers.",
"   </p>",
"   <p>",
"    Various SNPs are associated with increased susceptibility to infection and poor outcomes. They include SNPs of genes that encode cytokines (eg, TNF, lymphotoxin-alpha, IL-10, IL-18, IL-1 receptor antagonist, IL-6, and interferon gamma), cell surface receptors (eg, CD14, MD2, toll-like receptors 2 and 4, and Fc-gamma receptors II and III), lipopolysaccharide ligands (lipopolysaccharide binding protein, bactericidal permeability increasing protein), mannose-binding lectin, heat shock protein 70, angiotensin I-converting enzyme, plasminogen activator inhibitor, and caspase-12 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1301300\">",
"    <span class=\"h1\">",
"     SYSTEMIC EFFECTS OF SEPSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread cellular injury may occur when the immune response becomes generalized; cellular injury is the precursor to organ dysfunction. The precise mechanism of cellular injury is not understood, but its occurrence is indisputable as autopsy studies have shown widespread endothelial and parenchymal cell injury. Mechanisms proposed to explain the cellular injury include: tissue ischemia (insufficient oxygen relative to oxygen need), cytopathic injury (direct cell injury by proinflammatory mediators",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other products of inflammation), and an altered rate of apoptosis (programmed cell death).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tissue ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant derangement in metabolic autoregulation, the process that matches oxygen availability to changing tissue oxygen needs, is typical of sepsis.",
"   </p>",
"   <p>",
"    In addition, microcirculatory and endothelial lesions frequently develop during sepsis. These lesions reduce the cross-sectional area available for tissue oxygen exchange, disrupting tissue oxygenation and causing tissue ischemia and cellular injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microcirculatory lesions &ndash; The microcirculatory lesions may be the result of imbalances in the coagulation and fibrinolytic systems, both of which are activated during sepsis.",
"     </li>",
"     <li>",
"      Endothelial lesions &ndash; The endothelial lesions may be a consequence of interactions between endothelial cells and activated polymorphonuclear leukocytes (PMNs). The increase in receptor-mediated neutrophil-endothelial cell adherence induces the secretion of reactive oxygen species, lytic enzymes, and vasoactive substances (nitric oxide, endothelin, platelet-derived growth factor, and platelet activating factor) into the extracellular milieu, which may injure the endothelial cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another factor contributing to tissue ischemia in sepsis is that erythrocytes lose their normal ability to deform within the systemic microcirculation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Rigid erythrocytes have difficulty navigating the microcirculation during sepsis, causing excessive heterogeneity in the microcirculatory blood flow and depressed tissue oxygen flux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cytopathic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proinflammatory mediators",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other products of inflammation may cause sepsis-induced mitochondrial dysfunction (eg, impaired mitochondrial electron transport) via a variety of mechanisms, including direct inhibition of respiratory enzyme complexes, oxidative stress damage, and mitochondrial DNA breakdown [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/32\">",
"     32",
"    </a>",
"    ]. Such mitochondrial injury leads to cytotoxicity. There are several lines of evidence that support this belief:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell culture experiments have shown that endotoxin, TNFa, and nitric oxide cause destruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysfunction of inner membrane and matrix mitochondrial proteins, followed by degeneration of the mitochondrial ultrastructure. These changes are followed by measurable changes in other cellular organelles by several hours [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/33\">",
"       33",
"      </a>",
"      ]. The end result is functional impairment of mitochondrial electron transport, disordered energy metabolism, and cytotoxicity.",
"     </li>",
"     <li>",
"      Studies using various animal models have found normal or supranormal oxygen tension in organs during sepsis, suggesting impaired oxygen utilization at the mitochondrial level. As examples, a study in resuscitated endotoxemic pigs found a supranormal ileomucosal oxygen tension [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/34\">",
"       34",
"      </a>",
"      ], while a study in endotoxemic rats found an elevated oxygen tension in the bladder epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical relevance of mitochondrial dysfunction in septic shock was suggested by a study of 28 critically ill septic patients who underwent skeletal muscle biopsy within 24 hours of admission to the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/36\">",
"     36",
"    </a>",
"    ]. Skeletal muscle ATP concentrations, a marker of mitochondrial oxidative phosphorylation, were significantly lower in the 12 patients who died of sepsis than in 16 survivors. In addition, there was an association between nitric oxide overproduction, antioxidant depletion, and severity of clinical outcome. Thus, cell injury and death in sepsis may be explained by cytopathic (or histotoxic) anoxia, which is an inability to utilize oxygen even when present.",
"   </p>",
"   <p>",
"    Mitochondria can be repaired or regenerated by a process called biogenesis. Mitochondrial biogenesis may prove to be an important therapeutic target, potentially accelerating organ dysfunction and recovery from sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis (also called programmed cell death) describes a set of regulated physiologic and morphologic cellular changes leading to cell death. This is the principal mechanism by which senescent or dysfunctional cells are normally eliminated and the dominant process by which inflammation is terminated once an infection has subsided.",
"   </p>",
"   <p>",
"    During sepsis, proinflammatory cytokines may delay apoptosis in activated macrophages and neutrophils, thereby prolonging or augmenting the inflammatory response and contributing to the development of multiple organ failure. Sepsis also induces extensive lymphocyte and dendritic cell apoptosis, which alters the immune response efficacy and results in decreased clearance of invading microorganisms. Apoptosis of lymphocytes has been observed at autopsies in both animal and human sepsis. The extent of lymphocyte apoptosis correlates with and the severity of the septic syndrome and the level of immunosuppression. Apoptosis has been also observed in parenchymal cells, endothelial, and epithelial cells. Several experiments studies show that inhibiting apoptosis protect animal from organ dysfunction and lethality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11516984\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical observations and animal studies suggest that the excess inflammation of sepsis may be followed by immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Among the evidence supporting this hypothesis, an observational study removed the spleens and lungs from 40 patients who died with active severe sepsis and then compared them with the spleens from 29 control patients and the lungs from 30 control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/43\">",
"     43",
"    </a>",
"    ]. The median duration of sepsis was four days. The secretion of proinflammatory cytokines (ie, tumor necrosis factor, interferon gamma, interleukin-6, and interleukin-10) from the splenocytes of patients with severe sepsis was generally less than 10 percent that of controls, following stimulation with either",
"    <span class=\"nowrap\">",
"     anti-CD3/anti-CD28",
"    </span>",
"    or lipopolysaccharide. Moreover, the cells from the lungs and spleens of patients with severe sepsis exhibited increased expression of inhibitory receptors and ligands, as well as expansion of suppressor cell populations, compared with cells from control patients. The inability to secrete proinflammatory cytokines combined with enhanced expression of inhibitory receptors and ligands suggests clinically relevant immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ORGAN-SPECIFIC EFFECTS OF SEPSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular injury described above, accompanied by the release of proinflammatory and antiinflammatory mediators, often progresses to organ dysfunction. No organ system is protected from the consequences of sepsis; those listed included in this section are the organ systems that are most often involved. Multiple organ dysfunction is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension due to diffuse vasodilation is the most severe expression of circulatory dysfunction in sepsis. It is probably an unintended consequence of the release of vasoactive mediators, whose purpose is to improve metabolic autoregulation (the process that matches oxygen availability to changing tissue oxygen needs) by inducing appropriate vasodilation. Mediators include the vasodilators prostacyclin and nitric oxide (NO), which are produced by endothelial cells.",
"   </p>",
"   <p>",
"    NO is believed to play a central role in the vasodilation accompanying septic shock, since NO synthase can be induced by incubating vascular endothelium and smooth muscle with endotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. When NO reaches the systemic circulation, it depresses metabolic autoregulation at all of the central, regional, and microregional levels of the circulation. In addition, NO may trigger an injury in the central nervous system that is localized to areas that regulate autonomic control [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another factor that may contribute to the persistence of vasodilation during sepsis is impaired compensatory secretion of antidiuretic hormone (vasopressin). This hypothesis is supported by a study that found that plasma vasopressin levels were lower in patients with septic shock than in patients with cardiogenic shock (3.1 versus 22.7",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    even though the groups had similar systemic blood pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/47\">",
"     47",
"    </a>",
"    ]. It is also supported by numerous small studies that demonstrated that vasopressin improves hemodynamics and allows other pressors to be withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H25#H25\">",
"     \"Use of vasopressors and inotropes\", section on 'Vasopressin and analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vasodilation is not the only cause of hypotension during sepsis. Hypotension may also be due to redistribution of intravascular fluid. This is a consequence of both increased endothelial permeability and reduced arterial vascular tone leading to increased capillary pressure.",
"   </p>",
"   <p>",
"    In addition to these diffuse effects of sepsis on the circulation, there are also localized effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the central circulation (ie, heart and large vessels), decreased systolic and diastolic ventricular performance due to the release of myocardial depressant substances is an early manifestation of sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Despite this, ventricular function may still be able to use the Frank Starling mechanism to increase cardiac output, which is necessary to maintain the blood pressure in the presence of systemic vasodilation. Patients with preexisting cardiac disease (eg, elderly patients) are often unable to increase their cardiac output appropriately.",
"     </li>",
"     <li>",
"      In the regional circulation (ie, small vessels leading to and within the organs), vascular hyporesponsiveness (ie, inability to appropriately vasoconstrict) leads to an inability to appropriately distribute systemic blood flow among organ systems. As an example, sepsis interferes with the redistribution of blood flow from the splanchnic organs to the core organs (heart and brain) when oxygen delivery is depressed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The microcirculation (ie, capillaries) may be the most important target in sepsis. Sepsis is associated with a decrease in the number of functional capillaries, which causes an inability to extract oxygen maximally (",
"      <a class=\"graphic graphic_algorithm graphicRef73725 \" href=\"UTD.htm?9/47/9982\">",
"       algorithm 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. Techniques including reflectance spectrophotometry and orthogonal polarization spectral imaging have allowed in vivo visualization of the sublingual and gastric microvasculature [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. Compared to normal controls or critically ill patients without sepsis, patients with severe sepsis have decreased capillary density [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/58\">",
"       58",
"      </a>",
"      ]. This may be due to extrinsic compression of the capillaries by tissue edema, endothelial swelling,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plugging of the capillary lumen by leukocytes or red blood cells (which lose their normal deformability properties in sepsis).",
"     </li>",
"     <li>",
"      At the level of the endothelium, sepsis induces phenotypic changes to endothelial cells. This occurs through direct and indirect interactions between the endothelial cells and components of the bacterial wall. These phenotypic changes may cause endothelial dysfunction, which is associated with coagulation abnormalities reduced leukocytes, decreased red blood cell deformability, upregulation of adhesion molecules, adherence of platelets and leukocytes, and degradation of the glycocalyx structure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/59\">",
"       59",
"      </a>",
"      ]. Diffuse endothelial activation leads to widespread tissue edema, which is rich in protein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Microparticles from circulating and vascular cells also participate in the deleterious effects of sepsis-induced intravascular inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial injury in the pulmonary vasculature during sepsis disturbs capillary blood flow and enhances microvascular permeability, resulting in interstitial and alveolar pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Neutrophil entrapment within the lung's microcirculation initiates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amplifies the injury in the alveolocapillary membrane. The result is pulmonary edema, which creates ventilation-perfusion mismatch and leads to hypoxemia. Such lung injury is prominent during sepsis, likely reflecting the lung's large microvascular surface area. Acute respiratory distress syndrome is a manifestation of these effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circulatory abnormalities typical of sepsis may depress the gut's normal barrier function, allowing translocation of bacteria and endotoxin into the systemic circulation (possibly via lymphatics, rather than the portal vein) and extending the septic response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. This is supported by animal models of sepsis, as well as a prospective cohort study that found that increased intestinal permeability (determined from the urinary excretion of orally administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    and mannose) was predictive of the development of multiple organ dysfunction syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reticuloendothelial system of the liver normally acts as the first line of defense in clearing bacteria and bacteria-derived products that have entered the portal system from the gut. Liver dysfunction can prevent the elimination of enteric-derived endotoxin and bacteria-derived products, which precludes the appropriate local cytokine response and permits direct spillover of these potentially injurious products into the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is often accompanied by acute renal failure. The mechanisms by which sepsis and endotoxemia lead to acute renal failure are incompletely understood. Acute tubular necrosis due to hypoperfusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxemia is one mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, systemic hypotension, direct renal vasoconstriction, release of cytokines (eg, tumor necrosis factor), and activation of neutrophils by endotoxin and FMLP (a three amino acid [fMet-Leu-Phe] chemotactic peptide in bacterial cell walls) may also contribute to renal injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of death is increased in patients with sepsis who develop renal failure. It is not well understood why this occurs. One factor may be the release of proinflammatory mediators as a result of leukocyte-dialysis membrane interactions when hemodialysis is necessary. Use of biocompatible membranes can prevent these interactions and may improve survival and the recovery of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/66\">",
"     66",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\", section on 'Complement activation, membrane biocompatibility, renal recovery, and survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In critically ill patients, it is thought that one modality of renal replacement therapy, hemofiltration, removes circulating nephrogenic toxins that may play a role in the pathogenesis of sepsis-induced acute renal failure. Initial studies suggested that the high volume mode of hemofiltration (high volume hemofiltration [HVHF]) offers benefit over conventional dialysis (hemodialysis, peritoneal dialysis, continuous renal replacement therapy) for the treatment of acute renal failure in sepsis. However, a 2013 Cochrane review that included pooled data from 64 patients enrolled in three randomized trials evaluating HVHF compared to conventional hemodialysis for the treatment of acute renal failure in patients with severe sepsis or septic shock, showed no measureable change in hospital or ICU mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/67\">",
"     67",
"    </a>",
"    ]. This suggests that there is insufficient evidence to recommend the routine use of HVHF over other forms of renal replacement therapy. Results from the High Volume in Intensive Care (IVOIRE) study comparing high-volume versus low-volume hemofiltration will help clarify the role of nephrogenic toxins and their removal by hemofiltration in critically ill patients with acute renal failure associated with sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link&amp;anchor=H5#H5\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\", section on 'Removal of immunomodulatory substances in sepsis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) complications occur frequently in septic patients, often before the failure of other organs. The most common CNS complications are an altered sensorium (encephalopathy). The pathogenesis of the encephalopathy is poorly defined. A high incidence of brain microabscesses was noted in one study, but the significance of hematogenous infection as the principal mechanism remains uncertain because of the heterogeneity of the observed pathology.",
"   </p>",
"   <p>",
"    CNS dysfunction has been attributed to changes in metabolism and alterations in cell signalling due to inflammatory mediators. Dysfunction of the blood brain barrier probably contributes, allowing increased leukocyte infiltration, exposure to toxic mediators, and active transport of cytokines across the barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/68\">",
"     68",
"    </a>",
"    ]. Mitochondrial dysfunction and microvascular failure both precede functional CNS changes, as measured through somatosensory evoked potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these neurological consequences of sepsis, there is growing recognition that the parasympathetic nervous system may be a mediator of systemic inflammation during sepsis. This is supported by numerous observations in various animal models. Afferent vagus nerve stimulation during sepsis increases the secretion of corticotropin-releasing hormone (CRH), ACTH, and cortisol; the last effect can be suppressed by subdiaphragmatic vagotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Parasympathetic tone affects thermoregulation, as experimental vagotomy attenuates the hyperthermic response to IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Efferent parasympathetic activity, mediated by acetylcholine, has an antiinflammatory effect on the cytokine profile, with decreased in vitro expression of the proinflammatory cytokines TNF, IL-1, IL-6 and IL-18 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/73\">",
"     73",
"    </a>",
"    ]. And, external vagal stimulation prevents the onset of shock following vagotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/73\">",
"     73",
"    </a>",
"    ], while an acetylcholine receptor agonist diminishes the pathologic response to sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5449/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed neurological consequences of sepsis, such as peripheral neuropathy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link\">",
"     \"Neuromuscular weakness related to critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5444006\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typically, a bacterial pathogen enters a sterile site in which resident cells can detect the invader and initiate the host response. The host response is initiated when innate immune cells, particularly macrophages, recognize and bind to microbial components. Binding immune cell surface receptors to microbial components initiates a series of steps that result in the phagocytosis of invading bacteria, bacterial killing, and phagocytosis of debris from injured tissue. These processes are associated with the production and release of a range of proinflammatory cytokines by macrophages, leading to the recruitment of additional inflammatory cells, such as leukocytes. This response is highly regulated by a mixture of proinflammatory and antiinflammatory mediators. When a limited number of bacteria invade, the local host responses are generally sufficient to clear the pathogens. The end result is normally tissue repair and healing. (See",
"      <a class=\"local\" href=\"#H5444041\">",
"       'Normal response to infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sepsis occurs when the release of proinflammatory mediators in response to an infection exceeds the boundaries of the local environment, leading to a more generalized response. It is uncertain why immune responses that usually remain localized sometimes spread beyond the local environment causing sepsis. The cause is likely multifactorial and may include the direct effects of invading microorganisms or their toxic products, release of large quantities of proinflammatory mediators, and complement activation. In this context, an anti-inflammatory response may reduce the toxic effects of the excessive inflammatory response, but may also compromise effective host protection from the infection. Some individuals may be genetically susceptible to developing sepsis. (See",
"      <a class=\"local\" href=\"#H1300788\">",
"       'Transition to sepsis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite a clear understanding of the inflammatory and coagulation mechanisms triggered during the early stage of severe sepsis, not much is known about the cellular aspects underlying the mechanisms that ultimately lead to organ dysfunction and death. Widespread cellular injury may occur when the immune response spreads beyond the site of infection causing sepsis. Cellular injury is the precursor to organ dysfunction. The precise mechanism of cellular injury is not understood, but proposed mechanisms include tissue ischemia (insufficient oxygen relative to oxygen need), cytopathic injury (direct cell injury by proinflammatory mediators",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other products of inflammation), and an altered rate of apoptosis (programmed cell death). The mechanism of organ failure in sepsis may relate to decreased oxygen utilization associated with mitochondrial dysfunction rather than or in addition to poor oxygen delivery to tissues. (See",
"      <a class=\"local\" href=\"#H1301300\">",
"       'Systemic effects of sepsis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cellular injury, accompanied by the release of proinflammatory and antiinflammatory mediators, often progresses to organ dysfunction. No organ system is protected from the consequences of sepsis. Those that are most commonly involved include the circulation, lung, gastrointestinal tract, kidney, and nervous system. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Organ-specific effects of sepsis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/1\">",
"      Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007; 20:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/2\">",
"      Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001; 410:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/3\">",
"      Movat HZ, Cybulsky MI, Colditz IG, et al. Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. Fed Proc 1987; 46:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/4\">",
"      van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/5\">",
"      Pruitt JH, Copeland EM 3rd, Moldawer LL. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock. Shock 1995; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/6\">",
"      Barriere SL, Lowry SF. An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/7\">",
"      Szabo G, Kodys K, Miller-Graziano CL. Elevated monocyte interleukin-6 (IL-6) production in immunosuppressed trauma patients. I. Role of Fc gamma RI cross-linking stimulation. J Clin Immunol 1991; 11:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/8\">",
"      Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/9\">",
"      Pinsky MR, Matuschak GM. Multiple systems organ failure: failure of host defense homeostasis. Crit Care Clin 1989; 5:199.",
"     </a>",
"    </li>",
"    <li>",
"     Pugin J. Recognition of bacteria and bacterial products by host immune cells in sepsis. In: Yearbook of Intensive Care and Emergency Medicine, Vincent JL (Ed), Springer-Verlag, Berlin 1996. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/11\">",
"      Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/12\">",
"      Tapper H, Herwald H. Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood 2000; 96:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/13\">",
"      Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/14\">",
"      Tracey, KJ, Beutler, B, Lowry, SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/15\">",
"      Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/16\">",
"      Lamping N, Dettmer R, Schr&ouml;der NW, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998; 101:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/17\">",
"      Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/18\">",
"      Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/19\">",
"      Huber-Lang MS, Riedeman NC, Sarma JV, et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002; 16:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/20\">",
"      Riedemann NC, Guo RF, Neff TA, et al. Increased C5a receptor expression in sepsis. J Clin Invest 2002; 110:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/21\">",
"      Furebring M, H&aring;kansson LD, Venge P, et al. Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care 2002; 6:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/22\">",
"      Huber-Lang MS, Younkin EM, Sarma JV, et al. Complement-induced impairment of innate immunity during sepsis. J Immunol 2002; 169:3223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/23\">",
"      Liu D, Lu F, Qin G, et al. C1 inhibitor-mediated protection from sepsis. J Immunol 2007; 179:3966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/24\">",
"      Liu D, Cai S, Gu X, et al. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003; 171:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/25\">",
"      Guerrero R, Velasco F, Rodriguez M, et al. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J Clin Invest 1993; 91:2754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/26\">",
"      Schmidt W, Stenzel K, Gebhard MM, et al. C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery 1999; 125:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/27\">",
"      Jansen PM, Eisele B, de Jong IW, et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998; 160:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/28\">",
"      Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/29\">",
"      Piagnerelli M, Boudjeltia KZ, Vanhaeverbeek M, Vincent JL. Red blood cell rheology in sepsis. Intensive Care Med 2003; 29:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/30\">",
"      Piagnerelli M, Boudjeltia KZ, Brohee D, et al. Modifications of red blood cell shape and glycoproteins membrane content in septic patients. Adv Exp Med Biol 2003; 510:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/31\">",
"      Kirschenbaum LA, Aziz M, Astiz ME, et al. Influence of rheologic changes and platelet-neutrophil interactions on cell filtration in sepsis. Am J Respir Crit Care Med 2000; 161:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/32\">",
"      Harrois A, Huet O, Duranteau J. Alterations of mitochondrial function in sepsis and critical illness. Curr Opin Anaesthesiol 2009; 22:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/33\">",
"      Crouser ED, Julian MW, Blaho DV, Pfeiffer DR. Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit Care Med 2002; 30:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/34\">",
"      VanderMeer TJ, Wang H, Fink MP. Endotoxemia causes ileal mucosal acidosis in the absence of mucosal hypoxia in a normodynamic porcine model of septic shock. Crit Care Med 1995; 23:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/35\">",
"      Rosser DM, Stidwill RP, Jacobson D, Singer M. Cardiorespiratory and tissue oxygen dose response to rat endotoxemia. Am J Physiol 1996; 271:H891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/36\">",
"      Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/37\">",
"      Haden DW, Suliman HB, Carraway MS, et al. Mitochondrial biogenesis restores oxidative metabolism during Staphylococcus aureus sepsis. Am J Respir Crit Care Med 2007; 176:768.",
"     </a>",
"    </li>",
"    <li>",
"     Marshall JC, Watson RW. Apoptosis in the resolution of systemic inflammation. In: Yearbook of Intensive Care and Emergency Medicine, Vincent JL (Ed), Springer-Verlag, Berlin 1997. p.100.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/39\">",
"      Coopersmith CM, Stromberg PE, Dunne WM, et al. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 2002; 287:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/40\">",
"      Schefold JC, Hasper D, Reinke P, et al. Consider delayed immunosuppression into the concept of sepsis. Crit Care Med 2008; 36:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/41\">",
"      Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/42\">",
"      Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009; 101:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/43\">",
"      Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306:2594.",
"     </a>",
"    </li>",
"    <li>",
"     Parrat JR, Stoclet JC. Vascular smooth muscle function under conditions of sepsis and ARDS. In: Role of Nitric Oxide in Sepsis and ARDS, Fink MP, Payen D (Eds), Springer-Verlag, Berlin 1995. p.44.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/45\">",
"      Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 2000; 161:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/46\">",
"      Sharshar T, Gray F, Lorin de la Grandmaison G, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet 2003; 362:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/47\">",
"      Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/48\">",
"      Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/49\">",
"      Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/50\">",
"      Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/51\">",
"      Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/52\">",
"      Price S, Anning PB, Mitchell JA, Evans TW. Myocardial dysfunction in sepsis: mechanisms and therapeutic implications. Eur Heart J 1999; 20:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/53\">",
"      Hoffmann JN, Werdan K, Hartl WH, et al. Hemofiltrate from patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic compounds. Shock 1999; 12:174.",
"     </a>",
"    </li>",
"    <li>",
"     Fink MP. Systemic and splanchnic hemodynamic derangements in the sepsis syndrome. In: Splanchnic ischemia and Multiple Organ Failure, Martson A, Bulkey GB, Giddian-Green RG, Haglund U (Eds), CV Mosby, St. Louis 1989. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/55\">",
"      Astiz ME, DeGent GE, Lin RY, Rackow EC. Microvascular function and rheologic changes in hyperdynamic sepsis. Crit Care Med 1995; 23:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/56\">",
"      Neviere R, Mathieu D, Chagnon JL, et al. Skeletal muscle microvascular blood flow and oxygen transport in patients with severe sepsis. Am J Respir Crit Care Med 1996; 153:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/57\">",
"      Temmesfeld-Wollbr&uuml;ck B, Szalay A, Mayer K, et al. Abnormalities of gastric mucosal oxygenation in septic shock: partial responsiveness to dopexamine. Am J Respir Crit Care Med 1998; 157:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/58\">",
"      De Backer D, Creteur J, Preiser JC, et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002; 166:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/59\">",
"      Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/60\">",
"      De Backer D, Donadello K, Favory R. Link between coagulation abnormalities and microcirculatory dysfunction in critically ill patients. Curr Opin Anaesthesiol 2009; 22:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/61\">",
"      Luce JM. Pathogenesis and management of septic shock. Chest 1987; 91:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/62\">",
"      Ghosh S, Latimer RD, Gray BM, et al. Endotoxin-induced organ injury. Crit Care Med 1993; 21:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/63\">",
"      Hassoun HT, Kone BC, Mercer DW, et al. Post-injury multiple organ failure: the role of the gut. Shock 2001; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/64\">",
"      Upperman JS, Deitch EA, Guo W, et al. Post-hemorrhagic shock mesenteric lymph is cytotoxic to endothelial cells and activates neutrophils. Shock 1998; 10:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/65\">",
"      Doig CJ, Sutherland LR, Sandham JD, et al. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients. Am J Respir Crit Care Med 1998; 158:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/66\">",
"      Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994; 331:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/67\">",
"      Borthwick EM, Hill CJ, Rabindranath KS, et al. High-volume haemofiltration for sepsis. Cochrane Database Syst Rev 2013; 1:CD008075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/68\">",
"      Iacobone E, Bailly-Salin J, Polito A, et al. Sepsis-associated encephalopathy and its differential diagnosis. Crit Care Med 2009; 37:S331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/69\">",
"      Rosengarten B, Hecht M, Auch D, et al. Microcirculatory dysfunction in the brain precedes changes in evoked potentials in endotoxin-induced sepsis syndrome in rats. Cerebrovasc Dis 2007; 23:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/70\">",
"      Gaykema RP, Dijkstra I, Tilders FJ. Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion. Endocrinology 1995; 136:4717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/71\">",
"      Fleshner M, Goehler LE, Schwartz BA, et al. Thermogenic and corticosterone responses to intravenous cytokines (IL-1beta and TNF-alpha) are attenuated by subdiaphragmatic vagotomy. J Neuroimmunol 1998; 86:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/72\">",
"      Romanovsky AA, Simons CT, Sz&eacute;kely M, Kulchitsky VA. The vagus nerve in the thermoregulatory response to systemic inflammation. Am J Physiol 1997; 273:R407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/73\">",
"      Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5449/abstract/74\">",
"      Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10:1216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1597 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5449=[""].join("\n");
var outline_f5_20_5449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5444006\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5444041\">",
"      NORMAL RESPONSE TO INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1300788\">",
"      TRANSITION TO SEPSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1301093\">",
"      Effects of microorganisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1300875\">",
"      Excess proinflammatory mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complement activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1302244\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1301300\">",
"      SYSTEMIC EFFECTS OF SEPSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tissue ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cytopathic injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11516984\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ORGAN-SPECIFIC EFFECTS OF SEPSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5444006\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1597|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/51/41789\" title=\"algorithm 1\">",
"      Mediator release in sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/47/9982\" title=\"algorithm 2\">",
"      Oxygen extraction in sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/46/9963\" title=\"table 1\">",
"      Effects of cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/58/24492\" title=\"table 2\">",
"      Plasma endotoxin levels sepsis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=related_link\">",
"      Neuromuscular weakness related to critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_20_5450="Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis";
var content_f5_20_5450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5450/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5450/contributors\">",
"     Donna B Greenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5450/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5450/contributors\">",
"     Joel Dimsdale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/20/5450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/20/5450/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/20/5450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization is a syndrome of nonspecific physical symptoms that cannot be fully explained by a known medical condition after appropriate investigation. In addition, the symptoms may be caused or exacerbated by anxiety, depression, and interpersonal conflicts, and it is common for somatization, depression, and anxiety to all occur together [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Somatization can be conscious or unconscious and may be influenced by a desire for the sick role or for personal gain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatization often occurs in primary care patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/5\">",
"     5",
"    </a>",
"    ]. It is a major public health problem that increases use of medical services independent of any accompanying psychiatric or nonpsychiatric disorder and leads to frustration in both the patient and the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/4,6-9\">",
"     4,6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the following issues related to somatization: epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis of specific disorders. Treatment of somatization and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=see_link\">",
"     \"Somatization: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"somatization\" refers to a syndrome consisting of physical symptoms that cannot be explained by a known medical disease and are associated with substantial psychosocial impairment. This syndrome has also been called \"medically unexplained symptoms,\" \"medically unexplained physical symptoms,\" \"functional somatic symptoms,\" and \"somatic symptom disorders.\"",
"   </p>",
"   <p>",
"    Somatization is an overarching term that encompasses many different illnesses, including disorders that are recognized and described in the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/10\">",
"     10",
"    </a>",
"    ] and World Health Organization's International Classification of Diseases-10th Revision (ICD-10) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/11\">",
"     11",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67901 \" href=\"UTD.htm?14/20/14668\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    DSM-IV-TR and ICD-10 both include a group of illnesses called somatoform disorders. The somatoform disorders within each diagnostic system mostly overlap, but not entirely (",
"    <a class=\"graphic graphic_table graphicRef67901 \" href=\"UTD.htm?14/20/14668\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, DSM-IV-TR and ICD-10 include factitious disorder and malingering. Other diagnoses not recognized by these diagnostic systems include abridged somatization and multisomatoform disorder (",
"    <a class=\"graphic graphic_table graphicRef67901 \" href=\"UTD.htm?14/20/14668\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The different terms and diagnoses used to describe patients with somatization can be confusing, partly because some of them sound similar but have different meanings. As an example, somatization, somatoform disorders, somatization disorder, abridged somatization, and multisomatoform disorder are distinct categories. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The various terms and definitions exist because unexplained physical symptoms are poorly understood, and there is controversy about what these symptoms represent. The confusion, lack of precision, and controversy about these terms have stimulated efforts to improve the diagnostic classification of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/1,12-16\">",
"     1,12-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic uses the term \"somatization\" to refer to patients with unexplained physical symptoms, because it is often not essential to diagnose a specific type of disorder. Rather, somatization can be viewed as an illness with a spectrum of expression ranging from the exaggeration of common symptoms to unrelenting, disabling symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/17\">",
"     17",
"    </a>",
"    ]. The same principles of management apply to patients across the spectrum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization is common in the general population. More than 50 percent of patients presenting to outpatient medical clinics with a physical complaint do not have a medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/18-21\">",
"     18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatization, defined in one study as four or more unexplained physical symptoms in men and six or more unexplained physical symptoms in women, occurred in 17 percent of patients in primary care settings and 4 percent of the general US population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/9\">",
"     9",
"    </a>",
"    ]. Risk factors for somatization include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Fewer years of education",
"     </li>",
"     <li>",
"      Minority ethnic status",
"     </li>",
"     <li>",
"      Low socioeconomic status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of 21 European studies found the median 12-month prevalence rate for any somatoform disorder was 6 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatization disorder as defined by DSM-IV-TR is uncommon. The lifetime prevalence in the general US population is 0.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/9\">",
"     9",
"    </a>",
"    ]. Less than 1 percent of patients who present with unexplained somatic symptoms meet criteria for DSM-IV-TR somatization disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Health care utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization increases use of medical services independent of any accompanying psychiatric or nonpsychiatric medical disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ]. One study found primary care patients with somatization visited their outpatient clinic significantly more often during five years of follow-up compared to patients without somatization (34 versus 23 visits) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/24\">",
"     24",
"    </a>",
"    ]. Another study identified somatization (with a high likelihood of being formally diagnosed with a somatoform disorder) in about 20 percent of 1500 consecutive patients who made scheduled visits to primary care physicians in urban and suburban hospital-based practices [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/8\">",
"     8",
"    </a>",
"    ]. Somaticizing patients had significantly more annual primary care visits (4.9 versus 3.4), specialist visits (8.1 versus 4.9), emergency room visits (1.3 versus 0.5), and hospital admissions (0.3 versus 0.1), even after adjusting for sociodemographic characteristics, major medical morbidity, and comorbid anxiety and depression. Overall, patients with somatization utilized medical services (outpatient and inpatient) twice as often compared to nonsomaticizing patients, and generated twice the costs for medical care. The difference in costs between the two groups represented 16 percent of the total costs for the entire 1500 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Psychosocial functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization is consistently associated with impaired functioning and disability, independent of any existing psychiatric and nonpsychiatric medical comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/25\">",
"     25",
"    </a>",
"    ]. As an example, studies in primary care settings that compared somatizing patients to nonsomaticizing patients found significantly higher rates of unemployment (29 versus 15 percent) and impaired occupational functioning (55 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy exists whether somatization is to be considered a purely psychiatric disorder, or if it should be viewed as a syndrome of multiple unexplained symptoms that complicate the presentation of a general medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetic basis for somatization is not clear. Some, but not all studies, indicate a familial pattern for somatization. The familial aggregation may be due to genetic or environmental factors, or both. In addition, a genetic influence may represent an inherited predisposition to general distress, and not specifically to somatization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/29\">",
"     29",
"    </a>",
"    ]. Representative studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of patients with somatization disorder, about 20 percent of the female first-degree relatives also had the disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/30\">",
"       30",
"      </a>",
"      ]. Male relatives were more likely to have a substance use disorder or antisocial personality disorder.",
"     </li>",
"     <li>",
"      A family study examined 72 first-degree relatives of 19 patients with hypochondriasis and 97 relatives of 24 controls. There was no increase in the rate of hypochondriasis among the relatives of hypochondriasis patients compared with the relatives of controls [",
"      <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Childhood sexual abuse and recent exposure to physical or sexual violence are consistently associated with somatization in adult women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. A systematic review and meta-analysis involving 4640 patients found an association between a history of sexual abuse and lifetime diagnosis of functional gastrointestinal disorders (OR 2.4, 95% CI 1.4-4.3), nonspecific chronic pain (OR 2.2, 1.5-3.2), psychogenic seizures (OR 3.0, 1.1-4.7), and chronic pelvic pain (OR 2.7, 1.7-4.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/35\">",
"     35",
"    </a>",
"    ]. For victims of rape, associations were observed between rape and a lifetime diagnosis of fibromyalgia (OR 3.4, 1.5-7.5), chronic pelvic pain (OR 3.3, 1.02-10.53), and functional gastrointestinal disorders (OR 4.0, 1.9-8.6).",
"   </p>",
"   <p>",
"    Physical symptoms may offer a means to express distress when patients do not easily express emotions in words (alexithymia) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients may also come to the clinician with physical complaints when psychiatric symptoms have great stigma. The interpersonal model of somatization hypothesizes that somatic symptoms represent care-seeking behavior in patients with insecure attachment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, somatization may involve an over-inclusive or unrealistic concept of good health, increased attention to bodily processes to detect possible signs of illness, catastrophic interpretations of bodily sensations, lack of external stimulation, expectations, operant conditioning, and difficulty with information processing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient's perception of symptoms affects how they are reported, and perception is influenced by attitudes, beliefs, and psychologic distress [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In addition, some patients may be more prone to amplify symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Having a family member with a chronic illness during childhood may be a precursor to somatization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/38\">",
"     38",
"    </a>",
"    ]. The tendency to report functional or somatic symptoms tends to persist from childhood to adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once somatization has been established, behavior around the symptoms and sick role add another psychologic dimension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/39\">",
"     39",
"    </a>",
"    ]. The symptoms offer benefits such as social support, escape from obligations, disability payments, and a compromise for internal conflicts. At the same time, the symptoms are associated with loss of work, status, and independence.",
"   </p>",
"   <p>",
"    The tendency to somatize does not vary from culture to culture, and there are no significant cross-cultural differences in the rate and sociodemographic correlates of somatoform disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/44\">",
"     44",
"    </a>",
"    ]. One study of somatic symptoms of depressive disorder in 15 primary care centers in 14 countries did not show cultural variability [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/45\">",
"     45",
"    </a>",
"    ]. Although the frequency of somatoform disorders is similar across cultures, culture-specific manifestations are often present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential feature of somatization is a chronic history of unexplained physical symptoms, which the patient attributes to a nonpsychiatric disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/4,46\">",
"     4,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatizing patients present with a wide array of symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain symptoms, including headache, back pain, dysuria, joint pain, diffuse pain, and extremity pain",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms, including nausea, vomiting, abdominal pain, bloating, gas, and diarrhea",
"     </li>",
"     <li>",
"      Cardiopulmonary symptoms, including chest pain, dizziness, shortness of breath, and palpitations",
"     </li>",
"     <li>",
"      Pseudoneurologic symptoms, including fainting, pseudoseizures, amnesia, muscle weakness, dysphagia, double or blurred vision, difficulty walking, difficulty urinating, deafness, and hoarseness or aphonia",
"     </li>",
"     <li>",
"      Reproductive organ symptoms, including dyspareunia, dysmenorrhea, and burning in sex organs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preoccupation with symptoms may indicate somatization. Among first-time referrals to a neurology service, clinician recognition of this preoccupation was the primary identifying factor for patients with somatization. Asking about multiple symptoms beyond those related to the presenting neurological complaint added to detection of a somatoform disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The somatizing patient can also be recognized by the multiple unexplained symptoms, vague and inconsistent history, underlying sense of anguish, persistent unspoken demands, lack of factors that exacerbate or alleviate symptoms, and lack of positive findings on physical examination. These patients often elicit negative feelings from their clinician and are viewed as \"difficult patients\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23992?source=see_link\">",
"     \"The difficult patient encounter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coexisting psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization is strongly associated with anxiety and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/4,5,9,20,24,50\">",
"     4,5,9,20,24,50",
"    </a>",
"    ]. In a group of nearly 300 somatizing patients who visited primary care physicians in urban or suburban hospital-based practices, 58 percent had a comorbid anxiety or depressive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of 10,000 primary care patients, those with somatization were six times more likely to manifest anxiety or depression compared to those without somatization (30 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of physical symptoms, rather than the specific type of symptoms, is important in predicting a comorbid anxiety or depressive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/4,50\">",
"     4,50",
"    </a>",
"    ]. A systematic review of 47 studies found that as the number of somatic symptoms increased, so did the number of anxiety and depression symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/9\">",
"     9",
"    </a>",
"    ]. There are many other predictors of anxiety or depression in patients with somatization (",
"    <a class=\"graphic graphic_table graphicRef82079 \" href=\"UTD.htm?23/42/24235\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One study found a patient was more apt to report psychologic symptoms to a primary care clinician if the patient already had a relationship with that clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/45\">",
"     45",
"    </a>",
"    ]. Among those who presented with somatic symptoms of depression, 60 percent acknowledged other depressive symptoms, such as depressed mood or guilt, when the clinician asked.",
"   </p>",
"   <p>",
"    In addition to depression and anxiety, somatization is often associated with personality disorders. A study of 94 somatization patients, using structured interviews, found that 61 percent had at least one personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/52\">",
"     52",
"    </a>",
"    ]. The most common were avoidance, paranoia, self-defeating, and obsessive-compulsive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link\">",
"     \"Personality disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether there is an association between somatization and substance use disorder, with contradictory findings in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MEDICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient presenting with possible somatization includes taking a history, performing a physical examination, reviewing laboratory data, and communicating with other clinicians. A general medical illness may not be recognized because of insufficient attention to the history, physical examination, or laboratory tests; insufficient use of contemporary diagnostic techniques; the medical illness is due to iatrogenic adverse effects; or a new disease has yet to be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A medical and a psychosocial etiology for a patient's symptoms should be explored simultaneously so that the patient has confidence that medical needs are being addressed. In addition, patients who present with a new illness episode may be more willing to discuss psychosocial concerns at the onset of their evaluation, rather than after all medical examinations have failed to identify a cause for their symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/55\">",
"     55",
"    </a>",
"    ]. Many of these patients will have seen several clinicians. Establishing trust and minimizing the chance of humiliation is essential. The patient needs to feel respected and understood.",
"   </p>",
"   <p>",
"    A thorough examination will help the clinician and patient feel comfortable that no important diagnosis will be missed. Ancillary testing should be conservative. It is often the clinician who initially offers further diagnostic tests, even when patients offer cues that the etiology is psychiatric [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History of present illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In taking a history, the clinician should pay attention to how the physical symptoms are related to the patient's emotions and social situation, and if any stressful personal events such as losses have occurred. The pattern of pain should be assessed. The clinician should determine what exacerbates or alleviates the symptoms, and why the patient believes he or she is suffering. The patient may be convinced she has a specific disease, is seriously ill, or is dying. Assess whether the patient can be reassured.",
"   </p>",
"   <p>",
"    The patient should be asked about medications, including over-the-counter, prescription, and complimentary medications. Additionally, patients should be questioned about substance use, including alcohol.",
"   </p>",
"   <p>",
"    It is important to ask whether the patient has experienced physical or sexual abuse, whether the patient feels safe in her current relationships, and whether she feels threatened or afraid in any way, either at home or in other settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Past medical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patterns of somatization are characterized by a longitudinal course beginning in childhood. Patients may report that their parents were attentive only when they were sick.",
"   </p>",
"   <p>",
"    Ask about a lifetime history of anxiety disorder, depressive disorder, or multiple unexplained symptoms. In addition, prior treatment with psychotropic medications should be assessed.",
"   </p>",
"   <p>",
"    It is important to examine past medical records. The past history should be sufficient to document whether there is a pattern of suspected ailments, which were not confirmed pathologically, or a pattern of symptom preoccupation in different organ systems. A history of multiple surgical procedures without pathologic confirmation of disease raises the likelihood of somatization.",
"   </p>",
"   <p>",
"    The patient may have a history of changing doctors frequently or leaving the hospital against medical advice. Ask about compliance with a systematic evaluation of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The family history should be examined for a model of disability or somatization, and the presence of depression or anxiety disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Social history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consider the social context in which the physical symptoms appear, including likely stresses at the patient's stage of development (eg, desire to have children or care for children, work pressures, grief). Financial pressures, work, unemployment, disability history, history of arrests, time in prison, probation, and legal suits may provide context for the symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should satisfy the clinician that the patient does not have a medical disease. The examination provides a baseline for detecting change over time. Additionally, patients believe their complaints are taken seriously when a physical examination is performed.",
"   </p>",
"   <p>",
"    Clinicians should include a complete neurologic examination when they suspect the specific diagnosis of conversion disorder. Although the rate of misdiagnosis of conversion disorder was 29 percent in the 1950s, published studies since the 1970s show only 4 percent of patients diagnosed with conversion are subsequently found to have a documented medical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Psychogenic, nonepileptic seizures can be comorbid with epileptic seizures, and psychogenic seizures are often underestimated in patients with a known seizure disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing should be done judiciously to evaluate current and new physical symptoms. Often, extensive testing has previously been done to look for a diagnosis.",
"   </p>",
"   <p>",
"    Diagnostic tests are often ordered for patients with a low pretest probability of serious disease to provide reassurance, as well as to rule out illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/60\">",
"     60",
"    </a>",
"    ]. However, studies indicate that testing does not reassure patients. A meta-analysis of three open label randomized trials compared initial diagnostic testing (eg, cranial magnetic resonance imaging) with no testing in 757 patients with a low probability of disease based upon the presenting symptoms (eg, headache) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/61\">",
"     61",
"    </a>",
"    ]. Illness worry (concern that symptoms may represent serious illness) was comparable for both groups in the short term (&le;3 months) and long term (&gt;3 months); heterogeneity across studies was low. Additional analyses found that testing did not reduce nonspecific anxiety or resolve symptoms, but did lead to a small decrease in the number of subsequent clinic visits. &nbsp;",
"   </p>",
"   <p>",
"    Psychologic testing (eg, the Minnesota Multiphasic Personality Inventory [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]) or neuropsychologic testing is helpful to identify psychiatric illness such as depression for patients in whom there is diagnostic uncertainty following the clinical interview. Additionally, psychologic testing can help to assess the patient's strengths, decide which treatments are indicated, and monitor the impact of treatment over time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/64-67\">",
"     64-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization encompasses many different illnesses, including disorders that are recognized and described in the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ] and World Health Organization's International Classification of Diseases-10th Revision (ICD-10) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/69\">",
"     69",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67901 \" href=\"UTD.htm?14/20/14668\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The different diagnoses used to describe patients with somatization can be confusing (",
"    <a class=\"graphic graphic_table graphicRef67901 \" href=\"UTD.htm?14/20/14668\">",
"     table 1",
"    </a>",
"    ). In addition, there are a few differences between DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ] and ICD-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Terminology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Naming the illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should avoid the debate of whether symptoms are due to psychiatric or nonpsychiatric illness. Directly challenging the patient's belief that symptoms are caused by a medical condition may unintentionally undermine the relationship with the patient. It is more reasonable for the clinician to explain there is no evidence of a life-threatening illness, but rather, the patient has a well-described, although not well-understood, condition which results in the set of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients often feel better if they can have a name to describe a constellation of symptoms, but a specific psychiatric diagnosis may serve no purpose, and may even be detrimental [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/71\">",
"     71",
"    </a>",
"    ]. Patients diagnosed with a psychiatric illness can be informed that their condition is most likely treatable, especially mood and anxiety disorders. Clinicians should acknowledge the patient's physical and emotional suffering, emphasize that they regard the symptoms as real (eg, they are not \"in your head\"), and should assure the patient that the presence of a psychiatric disturbance or disorder does not negate the reality of his or her suffering [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/72\">",
"     72",
"    </a>",
"    ]. This approach may facilitate the patient's acceptance of a formal psychiatric intervention. Patients may nevertheless react defensively if clinicians raise the possibility that there is a psychopathology that which to be addressed and treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Somatoform disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatoform disorders are described in both DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ] and ICD-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/69\">",
"     69",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67901 \" href=\"UTD.htm?14/20/14668\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    DSM-IV-TR and ICD-10 somatoform disorders both include the following specific diagnoses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Somatization disorder",
"     </li>",
"     <li>",
"      Undifferentiated somatoform disorder",
"     </li>",
"     <li>",
"      Pain disorder",
"     </li>",
"     <li>",
"      Hypochondriasis",
"     </li>",
"     <li>",
"      Somatoform disorder not otherwise specified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is controversy about the validity of these diagnoses, because it is not clear that each specific diagnosis consists of a discrete, characteristic cluster of symptoms that is associated with a predictable longitudinal course of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. In addition, some authorities argue that the criteria or cut-off points used to distinguish cases are arbitrary [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ]. A systematic review of 47 studies that all used a standardized measure to diagnose somatization disorder or hypochondriasis in the general population or primary care settings concluded that these diagnoses cannot yet be regarded as definite psychiatric disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/9\">",
"     9",
"    </a>",
"    ]. The review questioned the validity of these diagnoses because they each lacked a consistent cluster of symptoms, there was considerable overlap between the two diagnoses, and the course of illness was variable.",
"   </p>",
"   <p>",
"    Somatoform disorders are differentiated from malingering or factitious disorder in that patients with somatoform disorders do not intentionally, voluntarily, or consciously produce their symptoms. By contrast, patients with malingering or factitious disorder do intentionally produce their symptoms. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Factitious disorder'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Malingering'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Classification in DSM-IV-TR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ] somatoform disorders are all characterized by the presence of physical symptoms which suggest a nonpsychiatric medical condition, but are not fully explained by such a condition. In addition, the symptoms are not fully explained by the direct effects of a substance or by another psychiatric disorder; the symptoms cause clinically significant distress or impairment of occupational, social, or other areas of functioning; and the symptoms are not intentionally or consciously produced, ie, they are not under voluntary control.",
"   </p>",
"   <p>",
"    DSM-IV-TR describes seven specific somatoform disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatization disorder &mdash; Numerous medically unexplained symptoms in different organ systems that lead to seeking treatment or significant impairment. All of the following are required at some point during the course of illness: four pain symptoms, two gastrointestinal tract symptoms, one sexual symptom, and one pseudoneurologic symptom (",
"      <a class=\"graphic graphic_table graphicRef73363 \" href=\"UTD.htm?19/33/19996\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Undifferentiated somatoform disorder &mdash; One or more medically unexplained physical symptoms lasting at least six months (",
"      <a class=\"graphic graphic_table graphicRef73919 \" href=\"UTD.htm?23/27/23995\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Conversion disorder &mdash; Symptoms or deficits of voluntary motor or sensory function that suggest a neurologic or general medical condition and are associated with psychologic factors (",
"      <a class=\"graphic graphic_table graphicRef79549 \" href=\"UTD.htm?43/46/44779\">",
"       table 5",
"      </a>",
"      ). Typically, there is a sudden onset of a dramatic, but physiologically impossible condition like paralysis, aphonia, blindness, deafness, or nonepileptic seizures. Unlike somatization disorder, patients with conversion disorder focus upon only one symptom.",
"     </li>",
"     <li>",
"      Somatoform pain disorder &mdash; Pain in one or more sites, of significant focus or severity, associated with psychological factors (",
"      <a class=\"graphic graphic_table graphicRef59089 \" href=\"UTD.htm?11/41/11931\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypochondriasis &mdash; Preoccupation with the fear of having a serious disease based upon misinterpretation of bodily symptoms or normal functions (",
"      <a class=\"graphic graphic_table graphicRef68413 \" href=\"UTD.htm?20/24/20875\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=see_link\">",
"       \"Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Body dysmorphic disorder &mdash; Preoccupation with an imagined or exaggerated defect in physical appearance.",
"     </li>",
"     <li>",
"      Somatoform disorder not otherwise specified &mdash; Disorders with somatoform symptoms that do not meet the criteria for a specific somatoform disorder. One example is a disorder that involves unexplained physical symptoms (eg, fatigue and headache) lasting less than six months, which are not explained by another psychiatric disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Classification in ICD-10",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to DSM-IV-TR, ICD-10 emphasizes the repeated presentation of physical symptoms with persistent requests for medical investigations, despite repeated negative findings and reassurances by clinicians that the symptoms have no physical basis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/69\">",
"     69",
"    </a>",
"    ]. ICD-10 includes the categories of somatization disorder, undifferentiated somatoform disorder, pain disorder, hypochondriasis, and somatoform disorder not otherwise specified, which are also included in DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, ICD-10 includes the following specific diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatoform autonomic dysfunction &mdash; The patient believes a physical disorder is causing symptoms that involve a particular organ or system under autonomic control, ie, the cardiovascular, gastrointestinal, respiratory, or genitourinary system. The diagnosis requires both symptoms that are based upon objective signs of autonomic arousal (eg, palpitations, sweating, and tremor) and symptoms that are more subjective (eg, intermittent pain, burning, heaviness, or tightness).",
"     </li>",
"     <li>",
"      Other somatoform disorders &mdash; This refers to symptoms that are not caused by a medical condition and are limited to specific systems or parts of the body not controlled by the autonomic nervous system. Examples include sensations of swelling, movements of the skin, and paresthesias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Abridged somatization disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;This diagnosis, not recognized by DSM-IV-TR or ICD-10, is defined as at least six lifetime, unexplained, physical symptoms in women, and four in men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Multisomatoform disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;This diagnostic category, also not recognized in the DSM-IV-TR or ICD-10, is defined as three or more currently bothersome, medically unexplained, physical symptoms, which are present for at least two years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/24\">",
"     24",
"    </a>",
"    ]. The focus on current symptoms avoids the problem patients may have in recalling lifetime unexplained symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Factitious disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential feature of factitious disorder is intentionally faking symptoms in order to assume the sick role, ie, to be a patient [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ]. No external incentives such as financial gain are present. Patients with factitious disorder tend to have some medical knowledge. Wound healing problems, excoriations, infection, bleeding, hypoglycemia, and gastrointestinal ailments are common presentations. The most extreme presentation, Munchausen syndrome, occurs in a subgroup of patients who feign disease, move from hospital to hospital, and submit to repeated procedures for an illness they have voluntarily manufactured [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/45,74,75\">",
"     45,74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=see_link\">",
"     \"Factitious disorder and Munchausen syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Malingering",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential feature of malingering is intentionally faking or grossly exaggerating symptoms for an obvious, external incentive such as avoiding work, avoiding criminal prosecution, obtaining financial compensation, or obtaining medications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ]. Clinicians should suspect malingering when any combination of the following is present: medical-legal context (eg, patient is referred by an attorney for evaluation), marked discrepancy between the patient's claimed distress or disability and the objective findings, noncompliance with diagnostic evaluation or treatment, and antisocial personality disorder.",
"   </p>",
"   <p>",
"    The motivation for symptom production in malingering is an external incentive, whereas in factitious disorder the motivation is to assume the role of patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care and other clinicians can use a brief screening instrument to assess for somatoform disorders. We suggest the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/76\">",
"     76",
"    </a>",
"    ]. This instrument screens for and provides categorical DSM-IV diagnoses for somatoform, depressive, anxiety, alcohol and eating disorders. It was specifically designed for use in primary care, is fully self-administered by the patient, has good diagnostic validity (sensitivity 75 percent, specificity 90 percent), and the median physician time to review the results is one to two minutes (",
"    <a class=\"graphic graphic_table graphicRef82674 \" href=\"UTD.htm?21/32/22019\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Self-report instruments, such as the Patient Health Questionnaire, have the advantage of saving the interviewer time, but are more prone to false positive diagnoses than clinician-administered instruments. Alternatively, clinician instruments, such as the Structured Clinical Interview for DSM-IV, use a structured diagnostic interview that enables the interviewer to clarify ambiguous or contradictory responses. However, these are labor intensive and generally reserved for specialized treatment or research settings.",
"   </p>",
"   <p>",
"    Other screening instruments are specific for somatization disorder, and emphasize the symptoms of amnesia, burning in sex organs, dysmenorrhea, lump in throat, painful extremities, shortness of breath, and vomiting. In one study, the presence of three of these seven symptoms was highly accurate for diagnosing somatization disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Classification in DSM-IV-TR'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms that occur in somatization occur in many other medical and psychiatric conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization frequently occurs in depression, and clinicians should consider major depression and dysthymia whenever somatization is present. In an international multicenter study, 69 percent of those with major depressive disorder presented with only somatic symptoms, and 50 percent had multiple unexplained symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/45\">",
"     45",
"    </a>",
"    ]. The diagnosis of major depression and dysthymia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic attacks are accompanied by a variety of somatic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ]. These include palpitations, tachycardia, chest pain, sweating, tremulousness, shortness of breath, sensation of smothering, choking, abdominal distress or nausea, diarrhea, dizziness, lightheadedness, feeling faint, paresthesia (numbness or tingling), chills, and flushing. Panic attack is diagnosed when the patient has a discrete period of fear during which four or more symptoms develop abruptly and reach a peak within 10 minutes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Substance use disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many symptoms of substance intoxication and withdrawal also occur in somatization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/53\">",
"     53",
"    </a>",
"    ]. These include weakness, fatigue, headaches, nausea, chest pain, vomiting, ataxia, tremors, blurred vision, and fasciculations. The recognition of drug abuse is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Syndromes of unclear etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may have a variety of syndromes including fibromyalgia, chronic fatigue syndrome, premenstrual dysphoric disorder, temporomandibular joint disorder, and idiopathic environmental intolerance (multiple chemical sensitivity) that incorporate many unexplained symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=see_link\">",
"     \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"     \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7194?source=see_link\">",
"     \"Temporomandibular joint dysfunction syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27242?source=see_link\">",
"     \"Overview of idiopathic environmental intolerance (multiple chemical sensitivity)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Nonpsychiatric medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization disorder overlaps with many medical conditions. A diagnosis of somatization disorder is more likely if symptoms involve multiple organ systems, and there is an early onset and chronic course in the absence of physical signs, structural abnormalities, and laboratory abnormalities. Medical conditions with vague symptoms and episodic or diffuse pain that may be confused with somatization disorder include multiple sclerosis, systemic lupus erythematosus, acute intermittent porphyria, and hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversion disorder may be erroneously diagnosed in cases when a neurologic condition is actually present, including multiple sclerosis, myasthenia gravis, and idiopathic or substance-induced dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatoform pain disorder should be distinguished from pain disorder associated with a medical condition, in which a medical illness has a major role in the onset, severity, exacerbation, or maintenance of the pain. If psychologic factors are present in pain disorder associated with a medical condition, they do not have a major role in the onset, severity, exacerbation, or maintenance of the pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16312?source=see_link\">",
"     \"Definition and pathogenesis of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypochondriasis is a diagnosis of exclusion, and should be diagnosed only after consideration of neurologic conditions such as multiple sclerosis or myasthenia gravis, endocrine conditions such as thyroid or parathyroid disease, diseases that affect multiple body systems such as systemic lupus erythematosus, and occult malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/20/5450/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatization is defined as physical symptoms which cannot be explained fully by a medical condition after appropriate investigation. Somatization can be viewed as a dimensional disorder, with a spectrum of expression ranging from the exaggeration of common symptoms to unrelenting disabling symptoms. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for somatization include female sex, fewer years of education, ethnic minority status, and low socioeconomic status. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The essential clinical feature of somatization is a chronic history of unexplained physical symptoms which the patient attributes to a nonpsychiatric disease. Somatizing patients may present with almost any symptom that occurs in patients with a nonpsychiatric disorder. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatization should be suspected in cases where the patient is preoccupied with symptoms, the history is vague or inconsistent, there is a lack of exacerbating or alleviating physical factors, and symptoms are not related to findings on the physical examination. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression, anxiety disorders, and personality disorders occur frequently in patients with somatization. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Coexisting psychiatric disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to perform a thorough history and physical examination. Ancillary laboratory testing should be judicious, and ordered only when specific diagnoses are suspected. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Medical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should avoid the debate of whether somatization is a psychiatric or nonpsychiatric illness, assure the patient there is no evidence of a life-threatening illness, emphasize the symptoms are real but are not well understood, and assure the patient that the presence of a psychiatric disturbance or disorder does not negate the reality of his or her suffering. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Naming the illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatization encompasses many different disorders described in DSM-IV-TR and ICD-10 (",
"      <a class=\"graphic graphic_table graphicRef67901 \" href=\"UTD.htm?14/20/14668\">",
"       table 1",
"      </a>",
"      ). Patients with somatoform disorders do not intentionally or consciously produce their symptoms. Patients with factitious disorder intentionally produce their symptoms to assume the sick role, and patients with malingering do so for personal gain. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians can use a brief screening instrument to assess for somatoform disorders. The Primary Care Evaluation of Mental Disorders Patient Health Questionnaire screens for and provides categorical DSM-IV diagnoses for somatoform, depressive, anxiety, alcohol, and eating disorders. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of somatization includes depression, anxiety disorders, and substance use disorders. Medical conditions that may be confused with somatization disorder include multiple sclerosis, systemic lupus erythematosus, acute intermittent porphyria, and hemochromatosis. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Differential Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Folks DB, Feldman MD, Ford CV. Somatoform disorders, factitious disorders, and malingering. In: Psychiatric Care of the Medical Patient, 2nd ed, Stoudemire A, Fogel B, Greenberg DB.  (Eds), Oxford, NY 2000. p.459.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/2\">",
"      Lipowski ZJ. Somatization: the experience and communication of psychological distress as somatic symptoms. Psychother Psychosom 1987; 47:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/3\">",
"      Kellner R. Hypochondriasis and somatization. JAMA 1987; 258:2718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/4\">",
"      Kroenke K, Rosmalen JG. Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders. Med Clin North Am 2006; 90:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/5\">",
"      L&ouml;we B, Spitzer RL, Williams JB, et al. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry 2008; 30:191.",
"     </a>",
"    </li>",
"    <li>",
"     Smith GR. Somatization in the Medical Setting, merican Psychiatric Press Inc., Washington, DC 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/7\">",
"      Barsky AJ, Ettner SL, Horsky J, Bates DW. Resource utilization of patients with hypochondriacal health anxiety and somatization. Med Care 2001; 39:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/8\">",
"      Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005; 62:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/9\">",
"      Creed F, Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res 2004; 56:391.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007. file://www.who.int/classifications/apps/icd/icd10online/ (Accessed on December 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/12\">",
"      L&ouml;we B, Mundt C, Herzog W, et al. Validity of current somatoform disorder diagnoses: perspectives for classification in DSM-V and ICD-11. Psychopathology 2008; 41:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/13\">",
"      Rief W, Isaac M. Are somatoform disorders 'mental disorders'? A contribution to the current debate. Curr Opin Psychiatry 2007; 20:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/14\">",
"      Mayou R, Kirmayer LJ, Simon G, et al. Somatoform disorders: time for a new approach in DSM-V. Am J Psychiatry 2005; 162:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/15\">",
"      Kroenke K. Somatoform disorders and recent diagnostic controversies. Psychiatr Clin North Am 2007; 30:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/16\">",
"      Creed F, Guthrie E, Fink P, et al. Is there a better term than \"medically unexplained symptoms\"? J Psychosom Res 2010; 68:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/17\">",
"      Katon W, Lin E, Von Korff M, et al. Somatization: a spectrum of severity. Am J Psychiatry 1991; 148:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/18\">",
"      Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med 1989; 86:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/19\">",
"      Katon W, Ries RK, Kleinman A. The prevalence of somatization in primary care. Compr Psychiatry 1984; 25:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/20\">",
"      Katon WJ, Walker EA. Medically unexplained symptoms in primary care. J Clin Psychiatry 1998; 59 Suppl 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/21\">",
"      Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med 1993; 153:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/22\">",
"      Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe--a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/23\">",
"      Kirmayer LJ, Robbins JM. Three forms of somatization in primary care: prevalence, co-occurrence, and sociodemographic characteristics. J Nerv Ment Dis 1991; 179:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/24\">",
"      Jackson JL, Kroenke K. Prevalence, impact, and prognosis of multisomatoform disorder in primary care: a 5-year follow-up study. Psychosom Med 2008; 70:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/25\">",
"      Harris AM, Orav EJ, Bates DW, Barsky AJ. Somatization increases disability independent of comorbidity. J Gen Intern Med 2009; 24:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/26\">",
"      Barsky AJ, Wyshak G, Klerman GL, Latham KS. The prevalence of hypochondriasis in medical outpatients. Soc Psychiatry Psychiatr Epidemiol 1990; 25:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/27\">",
"      Kellner R. Somatization. Theories and research. J Nerv Ment Dis 1990; 178:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/28\">",
"      Simon GE, VonKorff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Am J Psychiatry 1991; 148:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/29\">",
"      Deary V, Chalder T, Sharpe M. The cognitive behavioural model of medically unexplained symptoms: a theoretical and empirical review. Clin Psychol Rev 2007; 27:781.",
"     </a>",
"    </li>",
"    <li>",
"     Yutzy SH, Parish BS. Somatoform disorders. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed, Galanter M, Kleber HD.  (Eds), American Psychiatric Publishing, Washington, DC 2008. p.609.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/31\">",
"      Noyes R Jr, Holt CS, Happel RL, et al. A family study of hypochondriasis. J Nerv Ment Dis 1997; 185:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/32\">",
"      Morrison J. Childhood sexual histories of women with somatization disorder. Am J Psychiatry 1989; 146:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/33\">",
"      Eberhard-Gran M, Schei B, Eskild A. Somatic symptoms and diseases are more common in women exposed to violence. J Gen Intern Med 2007; 22:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/34\">",
"      Roelofs K, Spinhoven P. Trauma and medically unexplained symptoms towards an integration of cognitive and neuro-biological accounts. Clin Psychol Rev 2007; 27:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/35\">",
"      Paras ML, Murad MH, Chen LP, et al. Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis. JAMA 2009; 302:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/36\">",
"      Nemiah JC. A reconsideration of psychological specificity in psychosomatic disorders. Psychother Psychosom 1982; 38:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/37\">",
"      Noyes R Jr, Stuart SP, Watson DB. A reconceptualization of the somatoform disorders. Psychosomatics 2008; 49:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/38\">",
"      Rief W, Broadbent E. Explaining medically unexplained symptoms-models and mechanisms. Clin Psychol Rev 2007; 27:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/39\">",
"      Waddell G, Bircher M, Finlayson D, Main CJ. Symptoms and signs: physical disease or illness behaviour? Br Med J (Clin Res Ed) 1984; 289:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/40\">",
"      Waddell G, Newton M, Henderson I, et al. A Fear-Avoidance Beliefs Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability. Pain 1993; 52:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/41\">",
"      Barsky AJ, Wyshak G. Hypochondriasis and somatosensory amplification. Br J Psychiatry 1990; 157:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/42\">",
"      Steinhausen HC, Winkler Metzke C. Continuity of functional-somatic symptoms from late childhood to young adulthood in a community sample. J Child Psychol Psychiatry 2007; 48:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/43\">",
"      Dhossche D, Ferdinand R, van der Ende J, Verhulst F. Outcome of self-reported functional-somatic symptoms in a community sample of adolescents. Ann Clin Psychiatry 2001; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/44\">",
"      Janca A, Isaac M, Ventouras J. Towards better understanding and management of somatoform disorders. Int Rev Psychiatry 2006; 18:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/45\">",
"      Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999; 341:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/46\">",
"      Hoedeman, R, Blankenstein, NA, van der Feltz-Cornelis, CM, et al. Consultation letters for medically unexplained physical symptoms. Cochrane Database of Syst Rev 2007; :CD006524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/47\">",
"      Fink P, Steen Hansen M, S&oslash;ndergaard L. Somatoform disorders among first-time referrals to a neurology service. Psychosomatics 2005; 46:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/48\">",
"      Hahn SR, Kroenke K, Spitzer RL, et al. The difficult patient: prevalence, psychopathology, and functional impairment. J Gen Intern Med 1996; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/49\">",
"      Hahn SR, Thompson KS, Wills TA, et al. The difficult doctor-patient relationship: somatization, personality and psychopathology. J Clin Epidemiol 1994; 47:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/50\">",
"      Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994; 3:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/51\">",
"      Clarke DM, Piterman L, Byrne CJ, Austin DW. Somatic symptoms, hypochondriasis and psychological distress: a study of somatisation in Australian general practice. Med J Aust 2008; 189:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/52\">",
"      Rost KM, Akins RN, Brown FW, Smith GR. The comorbidity of DSM-III-R personality disorders in somatization disorder. Gen Hosp Psychiatry 1992; 14:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/53\">",
"      Hasin D, Katz H. Somatoform and substance use disorders. Psychosom Med 2007; 69:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/54\">",
"      Dimsdale JE, Dantzer R. A biological substrate for somatoform disorders: importance of pathophysiology. Psychosom Med 2007; 69:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/55\">",
"      Bensing JM, Verhaak PF. Somatisation: a joint responsibility of doctor and patient. Lancet 2006; 367:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/56\">",
"      Ring A, Dowrick CF, Humphris GM, et al. The somatising effect of clinical consultation: what patients and doctors say and do not say when patients present medically unexplained physical symptoms. Soc Sci Med 2005; 61:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/57\">",
"      Spiegel BM, Kanwal F, Naliboff B, Mayer E. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/58\">",
"      Stone J, Smyth R, Carson A, et al. Systematic review of misdiagnosis of conversion symptoms and \"hysteria\". BMJ 2005; 331:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/59\">",
"      Mari F, Di Bonaventura C, Vanacore N, et al. Video-EEG study of psychogenic nonepileptic seizures: differential characteristics in patients with and without epilepsy. Epilepsia 2006; 47 Suppl 5:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/60\">",
"      Kroenke K. Diagnostic testing and the illusory reassurance of normal results: comment on \"reassurance after diagnostic testing with a low pretest probability of serious disease\". JAMA Intern Med 2013; 173:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/61\">",
"      Rolfe A, Burton C. Reassurance After Diagnostic Testing With a Low Pretest Probability of Serious Disease: Systematic Review and Meta-analysis. JAMA Intern Med 2013; 173:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/62\">",
"      Greene RL. The relative efficacy of F-K and the obvious and subtle scales to detect overreporting of psychopathology on the MMPI. J Clin Psychol 1988; 44:152.",
"     </a>",
"    </li>",
"    <li>",
"     Hathaway SR, McKinley JC. Minnesota Multiphasic Inventory Manual, Psychological Corp, New York 1983.",
"    </li>",
"    <li>",
"     Greene RL. Assessment of malingering and defensiveness by objective personality inventories. In: Clinical Assessment of Malingering and Deception, Rogers R.  (Ed), Guilford Press, New York 1988. p.124.",
"    </li>",
"    <li>",
"     Faust D. The detection of deception. In: Neurologic Clinics, Malingering and Conversion Reactions, Weintraub SM.  (Ed), Saunders, Philadelphia 1995. p.255.",
"    </li>",
"    <li>",
"     Clarkin JF, Howieson DB, McClough J. The role of psychiatric measures in assessment and treatment. In: The American Psychiatric Publishing Textbook of Psychiatry, 5th ed, Hales RE, Yudofsky SC, Gabbard GO.  (Eds), American Psychiatric Publishing, Washington, DC 2008. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/67\">",
"      Dimsdale J, Creed F, DSM-V Workgroup on Somatic Symptom Disorders. The proposed diagnosis of somatic symptom disorders in DSM-V to replace somatoform disorders in DSM-IV--a preliminary report. J Psychosom Res 2009; 66:473.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007. Available online at: www.who.int/classifications/apps/icd/icd10online/ (Accessed on December 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/70\">",
"      Sharpe M, Carson A. \"Unexplained\" somatic symptoms, functional syndromes, and somatization: do we need a paradigm shift? Ann Intern Med 2001; 134:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/71\">",
"      Epstein RM, Quill TE, McWhinney IR. Somatization reconsidered: incorporating the patient's experience of illness. Arch Intern Med 1999; 159:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/72\">",
"      Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med 1999; 130:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/73\">",
"      Allen LA, Gara MA, Escobar JI, et al. Somatization: a debilitating syndrome in primary care. Psychosomatics 2001; 42:63.",
"     </a>",
"    </li>",
"    <li>",
"     Barsky AJ, Stern TA, Greenberg DB, Cassem NH. Functional and somatic symptoms and somatoform disorders. In: Massachusetts General Hospital Handbook of General Hospital Psychiatry, 4th ed, Cassem NH, Stern TA, Rosenbaum JF, Jellinek MS.  (Eds), Mosby, New York 1997. p.305.",
"    </li>",
"    <li>",
"     Feldman MD, Ford CV. Patient or Pretender: Inside the Strange World of Factitious Disorders, John Wiley and Sons, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/76\">",
"      Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/20/5450/abstract/77\">",
"      Othmer E, DeSouza C. A screening test for somatization disorder (hysteria). Am J Psychiatry 1985; 142:1146.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7766 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5450=[""].join("\n");
var outline_f5_20_5450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Health care utilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Psychosocial functioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coexisting psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MEDICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History of present illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Past medical illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Social history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Naming the illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Somatoform disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Classification in DSM-IV-TR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Classification in ICD-10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Abridged somatization disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Multisomatoform disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Factitious disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Malingering",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Substance use disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Syndromes of unclear etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Nonpsychiatric medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7766\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7766|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/20/14668\" title=\"table 1\">",
"      Somatization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/42/24235\" title=\"table 2\">",
"      Predictors of disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/33/19996\" title=\"table 3\">",
"      Dx criteria somatization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/27/23995\" title=\"table 4\">",
"      DSM undiff somatoform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/46/44779\" title=\"table 5\">",
"      Dx criteria conversion dis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/41/11931\" title=\"table 6\">",
"      Dx criteria pain disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/24/20875\" title=\"table 7\">",
"      Dx criteria hypochondria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/32/22019\" title=\"table 8\">",
"      PHQ",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=related_link\">",
"      Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16312?source=related_link\">",
"      Definition and pathogenesis of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=related_link\">",
"      Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27242?source=related_link\">",
"      Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=related_link\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=related_link\">",
"      Somatization: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7194?source=related_link\">",
"      Temporomandibular joint dysfunction syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23992?source=related_link\">",
"      The difficult patient encounter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_20_5451="Dosing of newer penicillins";
var content_f5_20_5451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of newer penicillins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal unit dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal dose interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing changes in severe renal",
"failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticarcillin",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Q4h",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piperacillin",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        Q4-6h&bull;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dose given at each normal dose interval, ie, 3g Q4h for ticarcillin.",
"     <br>",
"      &bull; These drugs have dose-dependent pharmacokinetics and can be given as 4 g Q6h.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5451=[""].join("\n");
var outline_f5_20_5451=null;
var title_f5_20_5452="WHO classif panc cyst neopl";
var content_f5_20_5452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization classification of pancreatic cystic neoplasms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Serous cystic tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Serous cystadenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Serous microcystic adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Serous oligocystic adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serous cystadenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mucinous cystic neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucinous cystadenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucinous cystic neoplasm with moderate dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mucinous cystadenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Noninvasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Invasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intraductal papillary mucinous neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraductal papillary mucinous adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraductal papillary mucinous neoplasm with moderate dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Intraductal papillary mucinous carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Noninvasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Invasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Solid pseudopapillary neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solid pseudopapillary neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solid pseudopapillary carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zamboni G, Kloeppel G, Hruban RH, et al. Mucinous cystic neoplasms of the pancreas. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, Aaltonen LA, Hamilton SR (Eds), IARC Press, Lyon, France 2000. p.234.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5452=[""].join("\n");
var outline_f5_20_5452=null;
var title_f5_20_5453="SBRT LC stage1 lung CA";
var content_f5_20_5453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of local control results for SBRT treatment of stage I lung tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Local control in percent (time point)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Timmerman",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        18 to 24 Gy x 3 fractions",
"       </td>",
"       <td>",
"        90 (2 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zimmerman",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        12.5 Gy x 3 fractions",
"       </td>",
"       <td>",
"        87 (3 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nyman",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        15 Gy x 3 fractions",
"       </td>",
"       <td>",
"        80 (crude)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fritz",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        30 Gy x 1",
"       </td>",
"       <td>",
"        80 (3 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baumann",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        15 Gy x 3",
"       </td>",
"       <td>",
"        80 (3 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Timmerman",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        20 to 22 Gy x 3",
"       </td>",
"       <td>",
"        95 (2+ years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nagata",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        12 Gy x 4",
"       </td>",
"       <td>",
"        94 (3 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hara",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        30 to 34 Gy x 1",
"       </td>",
"       <td>",
"        80 (3 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xia",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        5 Gy x 10",
"       </td>",
"       <td>",
"        95 (3 years)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. McGarry, RC, Papiez, L, Williams, M, et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study. Int J Radiat Oncol Biol Phys 2005; 63:1010.",
"     <br>",
"      2. Timmerman, R, Papiez, L, McGarry, R, et al. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003; 124:1946.",
"      <br>",
"       3. Zimmermann, FB, Geinitz, H, Schill, S, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005; 48:107.",
"       <br>",
"        4. Nyman, J, Johansson, KA, Hulten, U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer: Mature results for medically inoperable patients. Lung Cancer 2006; 51:97.",
"        <br>",
"         5. Fritz, P, Kraus, HJ, Muhlnickel, W, et al. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol 2006; 1:30.",
"         <br>",
"          6. Baumann, P, Nyman, J, Lax, I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer: A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006; 45:787.",
"          <br>",
"           7. Timmerman, R, McGarry, R, Yiannoutsos, C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24:4833.",
"           <br>",
"            8. Nagata, Y, Takayama, K, Matsuo, Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005; 63:1427.",
"            <br>",
"             9. Hara, R, Itami, J, Kondo, T, et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer 2006; 106:1347.",
"             <br>",
"              10. Xia, T, Li, H, Sun, Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 66:117.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5453=[""].join("\n");
var outline_f5_20_5453=null;
var title_f5_20_5454="Chemo regimens met CRC";
var content_f5_20_5454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"13%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Irinotecan",
"       </td>",
"       <td class=\"subtitle1\">",
"        Oxaliplatin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Leucovorin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fluorouracil/capecitabine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Schedule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FOLFIRI",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        180 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over two hours day 1",
"       </td>",
"       <td>",
"        Fluorouracil 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        bolus day 1, followed by 2400 to 3000 mg/m",
"        <sup>",
"         2&Delta;",
"        </sup>",
"        over 46 hours, continuous infusion",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Douillard regimen",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        180 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        leucovorin over two hours days 1 and 2 before fluorouracil",
"       </td>",
"       <td>",
"        Fluorouracil 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        bolus then 600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 22 hours days 1 and 2",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FOLFOX 4",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over two hours days 1 and 2 before fluorouracil",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Fluorouracil 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        bolus then 600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 22 hours days 1 and 2",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FOLFOX 6",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over two hours day 1",
"       </td>",
"       <td>",
"        Fluorouracil 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        bolus day 1, followed by 2400 to 3000 mg/m",
"        <sup>",
"         2&Delta;",
"        </sup>",
"        over 46 hours, continuous infusion",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Modified FOLFOX 6",
"        <sup>",
"         [4,5]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        350 mg total dose over two hours day 1",
"       </td>",
"       <td>",
"        Fluorouracil 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        bolus day 1, followed by 2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 46 hours",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FOLFOX 7",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        130 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over two hours day 1",
"       </td>",
"       <td>",
"        Fluorouracil 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        bolus, then 2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 46 hours",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Modified FOLFOX 7",
"        <sup>",
"         [7]",
"        </sup>",
"        (Optimox)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over two hours day 1",
"       </td>",
"       <td>",
"        Fluorouracil 3000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 46 hours",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Modified FOLFOX 7",
"        <sup>",
"         [8]",
"        </sup>",
"        (CONcePT)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over two hours day 1",
"       </td>",
"       <td>",
"        Fluorouracil 2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 46 hours",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        XELOX",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        130 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Capecitabine 1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        orally twice per day on days 1 to 14",
"       </td>",
"       <td>",
"        Every three weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FOLFOXIRI",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        165 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        day 1",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        leucovorin over two hours day 1",
"       </td>",
"       <td>",
"        Fluorouracil 3200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 48 hours",
"       </td>",
"       <td>",
"        Every two weeks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All doses shown are for intravenous (IV) administration, except capecitabine.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Leucovorin doses given for the d,l racemic mixture.",
"     <br/>",
"     &Delta; 2400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     dose is commonly used.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     The original trial report indicated a leucovorin dose of 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     daily, but this was an error, and the correct dose used in the protocol was 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (R Goldberg, personal communication).",
"     <br/>",
"     &sect; FOLFOX7 was administered with bevacizumab (5 mg/kg every two weeks) in the CONCePT trial.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Tournigand C, et al. J Clin Oncol 2004; 22:229.",
"       </li>",
"       <li>",
"        Douillard JY, et al. Lancet 2000; 355:1041.",
"       </li>",
"       <li>",
"        Goldberg R, et al. J Clin Oncol 2004; 22:23.",
"       </li>",
"       <li>",
"        Cheeseman SL, et al. Br J Cancer 2002; 87:393.&nbsp;",
"       </li>",
"       <li>",
"        Hochster HS, et al. J Clin Oncol 2008; 26:3523.",
"       </li>",
"       <li>",
"        Maindrault-Goebel F, et al. Eur J Cancer 2001; 37:1000.",
"       </li>",
"       <li>",
"        Chibaudel B, et al. J Clin Oncol 2009; 27:5727.",
"       </li>",
"       <li>",
"        Grothey A, et al. J Clin Oncol 2008; 26S:abstract 4010.",
"       </li>",
"       <li>",
"        Falcone A. J Clin Oncol 2007; 25:1670.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5454=[""].join("\n");
var outline_f5_20_5454=null;
var title_f5_20_5455="Peutz Jeghers oral lesions";
var content_f5_20_5455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral lesions in Peutz-Jeghers syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph shows the characteristic circumoral pigmentation in a patient with the Peutz-Jeghers syndrome. The pigmentation may not be obvious as in this patient, and it should always be sought carefully in young patients presenting with unexplained gastrointestinal bleeding, particularly if there is a family history of such bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Pounder, RE, Allison, MC, Dhillon, AP. A Color Atlas of the Digestive System, Wolfe, London, p. 118.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_20_5455=[""].join("\n");
var outline_f5_20_5455=null;
